  
 
    
Official Title:  Protocol VIS410 -202, A Phase 2a Double-
blind, Placebo -controlled Study to As sess the 
Safety and Tolerability of a Single 
Intravenous Dose of VIS410 in Subj ects with 
Uncomplicated Influenza A Infection 
 
Study ID: [REMOVED]  
 
Document Date:  [ADDRESS_820783] Number  2015 -004546 -26 
Clinical Phase  2a 
Clinical Indication  Influenza infection  
Issue Date (Version)  14 March 2017 (Version  2.2) 
 
Sponsor  Visterra, Inc.  
One Kendall Square, Suite B3301 Cambridge, MA [ZIP_CODE] [LOCATION_002] of America  
Sponsor  Representative     
 
 
 
Page 2 of 75

Visterra, Inc.
Version 2.2
SIGNATURESClnucer, SruovPnormor vIS4l0-202
14 Mmch 2017
Signature [CONTACT_618076] A Phase 2a Double-blind, Placebo-controlled Study to Assess the Safety and
Tolerability of a Single Intravenous Dose of YIS410 in Subjects with Uncomplicated
Influenza A Infection
Name: [CONTACT_618077]6 Trevejo, MD, PhD
'This Clinical Study Protocol has been reviewed and approved by [CONTACT_618015].'
"7fr\a-
vIS410-202 Visterra Confidential Page2 of74
Visterra Inc.
VIS410-202 Clinical Study Report
Page 3 of 75
Signature [CONTACT_618078]:  A Phase 2a Double -blind, Placebo -controlled Study to Assess the Safety and 
Tolerability of a Single Intravenous Dose of VIS410 in Subjects  with Uncomplicated 
Influenza A Infection  
 
Name:   
[CONTACT_23682] :  
Address:   
  
  
 
‘I have read and understood all  sections of the protocol entitled , “A Phase 2a Double -blind, 
Placebo -controlled Study to Assess the Safety and Tolerability of a Single Intravenous Dose 
of VIS410 in Subjects with Uncomplicated Influenza A Infection.” 
 
I agree to supervise all aspects of the protocol and to conduct the clinical investigation in 
accordance with the Final Protocol, the International Conference on Harmonisation tripartite 
guideline E6(R1): Good Clinical Practice and all applicable government regulations. I will 
not make chang es to the protocol before consulting with Visterra, Inc., or implement protocol 
changes without independent ethics committee approval except to eliminate an immediate 
risk to subjects. I agree to administer study treatment only to subjects under my persona l 
supervision or the supervision of a subinvestigator. 
 
I will not supply the investigational product to any person not authorized to receive it. 
Confidentiality will be protected. Subject identity will not be disclosed to third parties or 
appear in any study reports or publications. 
 
I will not disclose information regarding this clinical investigation or publish results of the 
investigation without authorization from Visterra, Inc. ’ 
 
 
Signature:   
[CONTACT_1782]:   
 
Visterra Inc.
VIS410-202 Clinical Study Report
Page 4 of 75
PROTOCOL HISTORY  
Protocol History  
Visterra, Inc.  – VIS410- 202 
Document  Issue Date  Amendment Type  Comments  
Initial Clinical Study Protocol  6 January 2016  - This document  
Revised Clinical Study Protocol  14 September 2016    
Revised Clinical Study Protocol  12 October 2016  Country Specific -
South Africa  Inclusion of HIV testing at 
baseline  
Revised Clinical Study Protocol  14 March 2014  Country Specific 
South Africa  Modification of HIV 
exclusion criteria #[ADDRESS_820784] of Abbreviations and Definitions of Terms ........................................................... 19  
1. Introduction ............................................................................................................. 21  
1.1 Background Information ...................................................................................... 21  
1.2 Nonclinical Studies  .............................................................................................. 21  
1.3 Clinical Studies  .................................................................................................... 22  
1.4 Overall Rationale for the Study  ........................................................................... 27  
1.5 Risk Benefit Analysis  .......................................................................................... 27  
1.5.1  Potential Risks  ....................................................................................... 28  
1.5.2  Potential Benefits  ................................................................................... 29  
2. Study Objectives ...................................................................................................... 29  
2.1 Primary Objective  ................................................................................................ 29  
2.2 Secondary Objectives  .......................................................................................... 29  
2.3 Exploratory Objectives ........................................................................................ 29  
3. Study Endpoints  ...................................................................................................... 30  
3.1 Primary Endpoints ............................................................................................... 30  
3.2 Secondary Endpoints ........................................................................................... 30  
3.3 Exploratory Endpoints ......................................................................................... 30  
4. Study Design  ............................................................................................................ 30  
4.1 Overview of Study Design ................................................................................... 30  
4.2 Discussion of Study Design ................................................................................. 31  
4.3 Inclusion Criteria  ................................................................................................. 32  
4.4 Exclusion Criteria  ................................................................................................ 33  
5. Treatment(s)  ............................................................................................................ [ADDRESS_820785]  ............................................................................. 36  
6. Prior and Concomitant Therapy  ........................................................................... 37  
6.1 Prior medications  ................................................................................................. 37  
6.2 Permitted Concomitant Therapi[INVESTIGATOR_014]  ....................................................................... 37  
6.3 Excluded Concomitant Medications  .................................................................... 37  
7. Assessments  ............................................................................................................. 38  
7.1 Timing of Assessments  ........................................................................................ 38  
Visterra Inc.
VIS410-202 Clinical Study Report
Page 6 of 75
7.1.1  Screening Examination and Eligibility Screening  Form  ....................... 38  
7.1.2  Contraception Requirements ................................................................. 38  
7.1.3  Procedures for Enrollment of Eligible Subjects .................................... 39  
7.1.4  Clinical Assessments and Procedures .................................................... 39  
7.1.5  Virological Assessments  ....................................................................... 40  
7.1.6  Unscheduled Visits ................................................................................ 40  
7.2 Pharmacokinetic Evaluations  ............................................................................... 41  
7.2.1  Sample Collection and Handling ........................................................... 41  
7.2.2  Bioanalysis  ............................................................................................ 41  
7.2.3  Pharmacokinetic Parameters .................................................................. 41  
7.3 Illness Evaluations  ............................................................................................... 42  
7.3.1  Viral Shedding ....................................................................................... 42  
7.3.2  Signs and Symptoms of Influenza ......................................................... 42  
7.4 Immunology ......................................................................................................... 42  
7.4.1  ADA Response  ...................................................................................... 42  
7.4.2  Anti-Influenza Antibody Response ....................................................... 42  
7.5 Resistance Analysis  ............................................................................................. 43  
7.6 Safety Evaluations  ............................................................................................... 43  
7.6.1  Adverse Events  ...................................................................................... 43  
7.6.2  Clinical Laboratory Tests  ...................................................................... 43  
7.6.3  Vital Signs  ............................................................................................. 44  
7.6.4  Electrocardiography ............................................................................... 44  
7.6.5  Physical Examination  ............................................................................ 44  
7.7 Total Volume of Blood Sampling........................................................................ 44  
7.8 Appropriateness of Measurements  ...................................................................... 44  
8. Study Termination/Completion  ............................................................................. [ADDRESS_820786] Sample  ......................................... 47  
9.3.3  Pharmacokinetics  ................................................................................... 47  
9.3.4  Viral Shedding ....................................................................................... 48  
9.3.5  Signs and Symptoms of Influenza ......................................................... 49  
9.3.6  Immunology .......................................................................................... 49  
9.3.7  Exploratory Pharmacokinetic/Pharmacodynamic Analyses  .................. [ADDRESS_820787] ................................................ 54  
Visterra Inc.
VIS410-202 Clinical Study Report
Page 7 of 75
10.5  Outcome ............................................................................................................... 54  
10.6  Recording of Adverse Events  .............................................................................. 54  
10.7  Reporting of Serious Adverse Events .................................................................. 55  
10.8  Pregnancy  ............................................................................................................ 55  
10.9  Reporting of SAEs to Competent Authorities/Ethics Committees  ...................... [ADDRESS_820788] Retention  ................................................................................................. 63  
12.11  Use of Information and Publication ..................................................................... 63  
12.12  Registration of Clinical Studies and Disclosure of Results  ................................. 65  
12.13  Confidentiality  ..................................................................................................... 65  
13. References  ................................................................................................................ 65  
Appendix 1: Laboratory Assessments ........................................................................... 66  
Appendix 2: DMID Adult Toxicity Table  ..................................................................... [ADDRESS_820789] of Figures  
Figure 1.  Schematic Overview of the Study  ...................................................................31  
 
Visterra Inc.
VIS410-202 Clinical Study Report
Page 8 of 75
SYNOPSIS 
Name [CONTACT_66030]:  
Visterra, Inc.   (for national authority only)  
Name [CONTACT_618079]:  Not applicable  
Name [CONTACT_618080]:  VIS410  
Study Title : A Phase 2a Double -blind, Placebo -controlled Study to Assess the Safety and 
Tolerability of a Single Intravenous Dose of VIS410 in Subjects  with 
Uncomplicated Influenza A Infection 
Protocol Number  VIS410 -[ADDRESS_820790] Number  2015 -004546 -26 
Clinical Indication : Influenza infection  
Clinical Phase :  2a 
Number of Clinical 
Sites : Approximately 50 -75 sites worldwide  
Number of Subjects :  Approximately 150 
Objectives:  
Primary Objective : 
• Assess the safety and tolerability  of a single intravenous (IV) dose of  VIS410 in patients with 
uncomplicated influenza infection  
Secondary Objectives : 
• Evaluate the efficacy of VIS410 compared with placebo on the time to alleviation of clinical 
symptoms of acute uncomplicated influenza  
• Evaluate the effect of VIS410 on severity of influenza infection  
• Assess the pharmacokinetics of VIS410 in serum  
• Assess t he effects of VIS410 on viral shedding 
• Assess the immunogenicity of VIS410 
Exploratory Objectives : 
• Assess the pharmacokinetics of VIS410 from nasopharyngeal secretions  
• Asse ss viral isolates to determine  the emergence of VIS410- resistant virus es 
• Assess correlations between virology, safety, pharmacokinetics, viral shedding, clinical symptoms , 
and other endpoints  
• Assess the anti -influenza immune response  
Study Design:  
This is a Phase 2a randomized, double- blind, placebo- controlled study to be conducted in approximately 
[ADDRESS_820791] placebo. Subjects  will be assigned randomly to receive VIS410 at a dose of 2000 mg 
(low dose) or 4000 mg (high dose) or placebo (0.9% sodium chloride) at a ratio of 1:1:[ADDRESS_820792] a follow -up phone 
Visterra Inc.
VIS410-202 Clinical Study Report
Page 9 of 75
Name [CONTACT_66030]:  
Visterra, Inc.   (for national authority only)  
call in the evening of the dosing day  to ensure subjects ’ safety and well -being . Subjects  will return for follow -up 
visits on Days  3 (± 1 day) , 5 (±1 day) , 7 (±1 day), 14 (± 3 day s), 28 (±3 days) , 56 (±7 day s) and 100 (±7 days) . In 
addition, between clinic visits  up to Day 7 (e.g., on Days  2, 4 and 6)  subjects will receive a follow -up telephone 
call to ensure compliance with FluP RO Influenza Symptom Questionnaire  and review any new or worsening 
signs or symptoms.   
The Schedule of Assessments is presented in  Table [ADDRESS_820793] of care. The use of 
over-the-counter, symptom- modifying drugs such as non-steroidal anti- inflammatory drugs ( NSAID s), 
antihistamines, or pseudoephedrine are discouraged and paracetamol/acetaminophen should be encouraged as a 
replacement medication.  
In case of hospi[INVESTIGATOR_617977], subjects should be managed per standard of care and local guidelines, which may include use of neuraminidase inhibitors . An independent  Data Safety 
Monitoring Board ( DSMB) will be established to review all available safety data after [ADDRESS_820794] DSMB, the DSMB will convene if the overall relative gastrointestinal ( GI) adverse event rate reaches 50% 
or the rate of moderate GI adverse events reaches 25%. Study enrollment  and dosing  will continue whilst the 
DSMB  evaluates data.   
Based upon any safety assessments and after mutual agreement with the Investigator (or designee) and the Sponsor, the study may be temporarily or permanently halted.  
Dosing will temporarily pause  whilst the DSM B meets if : 
• a drug- related or unexpected drug -related SAE occurs in at least [ADDRESS_820795]  
• 25% or more subjects have  GI symptoms  of Grade [ADDRESS_820796] at the discretion of the DSMB based on review of safety data including GI adverse events.  
Study Population:  
Approximately one hundred fifty (150 ) subjects  will be enrolled in 3 equal arms : VIS410 2000 mg, 
VIS410 4000 mg, and  placebo. The subjects  will be carefully screened for eligibility.  
Inclusion Criteria:  
Subjects  meeting all of the following criteria are eligible to participate in this study:  
1. Male and female subjects  aged ≥18 years  and ˂65 years  
2. Women should fulfill one of the following criteria:  
a. Post-menopausal; either amenorrhea ≥12 months or follicle stimulating hormone >40  mIU/mL  as 
documented in their medical history .  
b. Surgically sterile; hysterectomy, bilateral oophorectomy, or tubal ligation.  
c. Women of childbearing potential participating in heterosexual sexual relations must be willing to 
use adequate contraception from screening until [ADDRESS_820797] -infusion, per Section  7.1.2 .  
3. Non-vasectomized (or vasectomized less than 6 months prior to dos ing) male subjects who have a 
female partner of childbearing potential must use an effective birth control method (see S ection  7.1.2 ) 
when having heterosexual intercourse, from screening until [ADDRESS_820798] on an adeq uate nasopharyngeal specimen in accordance with the manufacturer's instructions  
5. Presence of at least one respi[INVESTIGATOR_20321] (cough, sore throat, or nasal symptoms) of moderate to severe intensity , or presence of at least one constitutional symptom (myalgia [aches and pains], 
headache, feverishness, or fatigue) of moderate to severe intensity  
6. Onset of symptoms (time when the temperature was first measured as elevated  [temperature of 
≥100.4°F or ≥38°C ], OR the time when the subject  experienced at least one r espi[INVESTIGATOR_617978].
VIS410-202 Clinical Study Report
Page 10 of 75
Name [CONTACT_66030]:  
Visterra, Inc.   (for national authority only)  
least one constitutional symptom) no more than [ADDRESS_820799]  is able and willing to give voluntary written informed consent  
Exclusion Criteria:  
Subjects  meeting any of the following criteria are excluded from participation in this study:  
1. Use of NSAIDs or antihistamines within 6 hours of study drug dosing  with the exception of those used 
as part of the pretreatment regimen.  
2. History of intolerance or allergic response to monoclonal antibodies and/or pretreatment medications 
diphenhydramine, ibuprofen and acetylsalicylic acid ) 
3. History of receiving monoclonal  antibody products within [ADDRESS_820800] weight less than ( <) [ADDRESS_820801] -feeding, or considering becoming pregnant .  
9. Patients wit h hypoxemia requiring oxygen support.  
10. Clinical evidence of worsening of any chronic medical condition (temporally associated with the onset 
of symptoms of influenza) which, in the I nvestigator's opi[INVESTIGATOR_1649], indicates that such finding(s) could 
represent complications of influenza  
11. Presence of immunocompromised status due to chronic illness, previous organ transplant, or use of 
immunosuppressive medical therapy  including systemic steroids.  
12. Presence of known human immunodeficiency virus (HIV) infection PLUS any one of the following:  
a. A CD4 count ≤ 500 cells/mm3 (CD4 count obtained within the 3 months prior to screening)  
b. An Acquired Immune Deficiency Syndrome -defining illness.  (HIV testing required at 
screening visit for all patients with no documented HIV status within 3 months prior to screening.)  
13. Presence of known  chronic hepatitis B or hepatitis C. 
14. Receipt of any dose of antiviral therapy such as, but not limited to, rimantadine, amantadine, peramivir, zanamivir, laninamivir or oseltamivir in the [ADDRESS_820802], Dose, Mode of Administration:  
VIS410 ( 2000  mg or 4000 mg) will be administered IV over [ADDRESS_820803], Dose, Mode of Administration:  
Placebo, normal saline solution (0.9%), will be administered IV  over 2 hours  as a single 200-mL infusion  
Visterra Inc.
VIS410-202 Clinical Study Report
Page 11 of 75
Name [CONTACT_66030]:  
Visterra, Inc.   (for national authority only)  
followed by a [ADDRESS_820804] is administered .  
Study Drug Preparation : 
The required amount of VIS410 to be dosed ( 2000 mg or 4000 mg) will be diluted with normal saline up to a 
total volume of 200 mL; for placebo subjects, [ADDRESS_820805], u niform -length infusion lines will be used and microfilters will be provided by [CONTACT_1034].  
The infusion bag will be covered with an opaque sleeve in the pharmacy to maintain the study blind. The study 
drug will be administered IV at a rate of 100 mL/h, over 2 hours. After 200 mL of the diluted dose has been 
administered, the infusion will be stopped ; followed by a 25- mL saline flush . The infusion time may be longer 
at the Investigator’s discretion based on local infusion site -related symptoms up to a maximum of [ADDRESS_820806].  
Pretreatment: Subjects  will be given a pretreatment regimen of diphenhydramine [ADDRESS_820807] 2 h ours at the infusion center  and discharged if 
considered safe by [CONTACT_093]. Prior to discharge, all subjects will be counseled on the potential GI AEs 
and management of the se events .  
Study Duration:  
The total study duration for each subject  (screening through study exit) will be approximately  14 weeks  
(Day  100). 
Criteria for Evaluation : 
Primary Endpoints :  
• The proportion of subjects with adverse events ( AEs) and serious adverse events (SAEs) following 
administration of VIS410  
• The proportion of subjects  with treatment -emergent AEs (TEAEs) including hypersensitivity 
reaction, anaphylactic reaction , and AEs of special interest (AESIs) following dosing 
Secondary Endpoints : 
• The incidence, severity , and duration of signs and symptoms of influenza -like illness as assessed 
by [CONTACT_618016] a single IV dose of VIS410  
• Percentage of participants requiring hospi[INVESTIGATOR_617979]- related complications  
• Duration of hospi[INVESTIGATOR_617979] -related complications  
• Percentage of participants with complications of influenza  
• Percentage of participants with influenza A relapse/reinfection  
• VIS410 pharmacokinetic ( PK) param eters (C max, tmax, AUC 0-∞, AUC 0-last, t1/2, V d, CL) in serum  
• The difference between VIS410 and placebo treatment groups in viral AUC from nasopharyngeal swabs  
• The difference between VIS410 and placebo treatment groups in peak viral load  and time to 
resolut ion of viral load  from nasopharyngeal swabs  
• Titer of anti -VIS410 antibody -positive samples  
Exploratory Endpoints : 
• PK parameters (C max, tmax, AUC 0-∞, AUC 0-last, t1/2) of VIS410 from nasopharyngeal secretions  
Visterra Inc.
VIS410-202 Clinical Study Report
Page 12 of 75
Name [CONTACT_66030]:  
Visterra, Inc.   (for national authority only)  
• Genotypic and phenotypic assessment to determine the emergence of VIS410 -resistant viruses  
• Correlations between serum and /or nasopharyngeal PK with viral load , clinical symptoms , 
presence of anti -drug antibodies,  and additional endpoints  
• Titer of anti -influenza A antibodies by [CONTACT_618017] ( HAI) in serum 
• Correlations between virology and safety parameters  and/or additional parameters may be explored  
Statistical Methods:  
Sample size : 
Approximately one hundred fifty ( 150) subjects . No formal sample size calculations were done for this study.  
The sample size is consistent with Phase  2a studies to assess safety and tolerability.  VIS410 endpoints will 
compare aggregated VIS410 data as well as different dose levels of VIS410 to the placebo arm.  
Descriptive analyses of data from subject s wil l be performed for demographic characteristics, AEs, concomitant 
medication use, and PK parameters in serum and nasopharyngeal secretions  as described below. All calculations 
will use the actual times recorded in the electronic data capture ( EDC ) system for dosing and s ampling. 
Individual and mean (±  standard deviation [ SD]) or median concentrations versus time profiles will be plotted 
by [CONTACT_618018]. Additional plots and PK parameters may be generated as 
appropriate.  
Serum Pharmacokinetics   
Serum concentrations and the computed PK parameters will be listed by [CONTACT_618019]410. Summary statistics 
of serum concentrations and PK parameters will be presented including means, geometric means, standard 
deviations, CV, medi ans and ranges, as appropriate. Additional analyses and summaries may be generated as 
appropriate.  
The following PK parameters will be determined for VIS410 in serum:  
• Cmax: maximum observed serum concentration  
• Tmax: time of C max 
• AUC 0-∞: area under the seru m concentration -time curve from time 0 extrapolated to infinity  
• AUC 0-last: area under the serum concentration -time curve from time [ADDRESS_820808] measurable 
concentration  
• t1/2: terminal elimination half -life 
• CL: total clearance  
• Vd: volume of distribution  
 
PK data from this study will be also analyzed by [CONTACT_618020].  
Nasopharyngeal Secretion Pharmacokinetics  
Nasopharyngeal secretion concentrations and the computed PK parameters will be listed by [CONTACT_618019]410. 
Summary statistics of nasopharyn geal secretion concentrations and PK parameters will be presented including 
means, geometric means, standard deviations, CV, medians and ranges, as appropriate. Additional analyses  and 
summaries may be generated as appropriate.  
The following PK parameters will be determined for VIS410 from nasopharyngeal secretions : 
• Cmax: maximum observed concentration from nasopharyngeal secretions  
• Tmax: time of C max 
• AUC 0-∞: area under the nasopharyngeal secretion concentration -time curve from time 0 
extrapolated to infinity  
Visterra Inc.
VIS410-202 Clinical Study Report
Page 13 of 75
Name [CONTACT_66030]:  
Visterra, Inc.   (for national authority only)  
• AUC 0-last: area under the nasopharyngeal secretion concentration -time curve from time [ADDRESS_820809] 
measurable concentration  
• t1/2: terminal elimination half -life 
• Ratio of nasal: serum  AUC  
 
Additional PK parameters may be determined as appropriate. 
Adverse Events  
The original terms in the EDC system used by [CONTACT_618021] A 
will be fully described and coded according to the Medical Dictionary for Regulatory Activities (MedDRA 
current version 19). The reported AEs will be allocated to phases based on their start date. All AEs will be 
listed. All AEs with onset during the treatment phase (i.e., TEAEs) will be summarized.  
AEs will be summarized by [CONTACT_618022] d term, severity, 
relatedness, and seriousness.  
The difference in proportions of subjects with AEs,  TEAEs, AE SIs, and SAEs between treatment groups and 
their 95% CI will be calculated (primary safety endpoint). 
Special attention will be paid to those subj ects who died, discontinued the study drug due to an AE, or 
experienced a severe or serious AE. Summaries, listings, and narratives may be provided, as appropriate. 
Injection Site Tolerability  
Injection site tolerability is defined as  AEs demonstrating sig nificant injection site irritation or tissue damage. 
Injection site tolerability will be reported by [CONTACT_72246], treatment group , and time point.  
Complications of Influenza  
Complications of influenza are defined as pneumonia, myocarditis, worsening of chronic bronchitis, other chronic pulmonary diseases , sinus infection, otitis, and death . Complications of influenza will be reported by 
[CONTACT_72246], treatment group , and time point.  
Clinical Laboratory Tests  
Actual values and changes from baseline of each continuous biochemistry, hematology and urinalysis test will 
be evaluated by [CONTACT_618023]. For categorical 
urinalysis tests, frequency tables of actual values will be provided by [CONTACT_618024] . 
Relative changes in clinical laboratory test values compared to values at baseline will be evaluated according to the DMID grading table or in accordance with the normal ranges of the clinical laboratory (below, within, or 
above normal range) for parameters for which no toxicity grades are defined. A shift from baseline table of the 
abnormalities will be provided by [CONTACT_618025].  
A listing of subjects with any clinical laboratory test result outside the reference ranges will be provided.  
Vital Signs  
Actual values and changes from baseline of heart rate,  respi[INVESTIGATOR_697],  temperature, systolic blood pressure 
(SBP), and diastolic blood pressure ( DBP ) measurements will be evaluated by [CONTACT_618026].  
A shift from baseline table of vital sign abnormalities will be provided by [CONTACT_618027].  
Electrocardiography  
The ECG variables that will be analyzed are heart rate, PR interval, QRS interval, and QT interval. Values for 
QT corrected for heart rate (QTc) will be derived. QTc corrected according to Fridericia (QTcF) [6] will be the 
Visterra Inc.
VIS410-202 Clinical Study Report
Page 14 of 75
Name [CONTACT_66030]:  
Visterra, Inc.   (for national authority only)  
primary correction parameter.  
Actual values and changes from baseline of ECG variables will be evaluated by [CONTACT_618028].  
A shift from baseline table of ECG abnormalities will be provided by [CONTACT_618029]. For absolute QTcF interval prolongation (>450, >480, >500 ms ec) and changes from baseline (increase 
>30 and >60 ms ec), a frequency table by [CONTACT_618030].  
Signs and Symptoms of Influenza 
• Frequency tabulation of the occurrence and severity of each of the subject -reported symptoms of 
influenza -like illness by [CONTACT_618025]  
• Descriptive statistics of the duration of each of the subject -reported symptoms of influenza -like 
illness by [CONTACT_618031], treatment group , and time point using descript ive 
statistics:  
• Anti-VIS410 antibody titers by [CONTACT_618032]  
• Anti-influenza A antibodies by [CONTACT_618033]  
• HAI levels to determine a proper immune response to the influenza infection  
Exploratory Pharmacokinetic/Pharmacodynamic Analyses  
Various techniques will be used to explore exposure –response relationships, and to compare the strength of the 
relationship between each independent variable (e.g., AUC, C max, and concentration at specific time  point) and 
the dependent variables (e.g., viral AUC, peak viral load , and time to cessation of viral shedding, clinical 
symptoms , and additional endpoints).  These techniques may include graphical and statistical methods, including 
the creation of boxplots, spaghetti plots, histograms, and a variety of linear, nonlinear, or  logistic regression 
techniques and time -to-event methods. If appropriate, continuous independent variables will be evaluated as 
such, and as categorical variables (groupi[INVESTIGATOR_617980]).   
Anti- Drug Antibodies  
Anti-VIS410 antibody titer will be summarized by [CONTACT_181301].  
Physical Examination  
Abnormal findings in physical examination will be listed.  
 
Visterra Inc.
VIS410-202 Clinical Study Report
Page 15 of 75
TIME AND EVENTS SCHE DULE 
Table 1. Schedule of Assessments  
Study Time Point  
Screening 1 Day 1  Clinic Visit Day  Baseline  1 
Predose  
0 hour  
End of  
Infusion  
≥2 Hours  
from End of  
Infusion  3 (±1)  2 5 (±1)  2 7 (±1)  14 (±3)  28 (±3)  56 (±7)  100 (±7)  
FU/ET3 
Screening/Administrative Assessments  
Informed consent  X             
Inclusion/exclusion criteria  X             
Medical history and demographics  X             
Admission   X            
Discharge       X        
Nasopharyngeal swab for Rapid flu test 4 X             
Onset of symptoms interview  X             
Randomization   X            
Safety Assessments  5  
Supi[INVESTIGATOR_477499] 6 X    X         
Vital signs 7 X X 8   X X X X  X X X X 
Body temperature 9 X X 8   X X X–––––––––––––––––––––– X X X X 
Physical exam  X             
Targeted physical exam [ADDRESS_820810] 11 X            X 
Serology (HIV rapid test)  12 X             
Chemistry 13 X       X  X   X 
Visterra Inc.
VIS410-202 Clinical Study Report
Page 16 of 75
Study Time Point  
Screening 1 Day 1  Clinic Visit Day  Baseline  1 
Predose  
0 hour  
End of  
Infusion  
≥2 Hours  
from End of  
Infusion  3 (±1)  2 5 (±1)  2 7 (±1)  14 (±3)  28 (±3)  56 (±7)  100 (±7)  
FU/ET3 
Hematology  13 X       X  X   X 
Urinalysis  13 X       X  X   X 
Instructions conmeds and FluPRO  X             
Observation in unit     X X X        
FluPRO completion  14  X     X–––––––––––––––––––––– X    
FluPRO compliance       X X X X     
FluPRO collection, review and reinstructions        X X X     
AESIs   X––––––––––––––––––––––––––––––––––––––––––––––––––––– ––––––––––––––– X  X 15 
Concomitant therapy, AEs  2  X––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––– –––––––––––––– X 
Collection of SAEs   X––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––– ––––––––––– ––––– X 
Influenza complications   X––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––– –––––––––––––––– X 
Study Agent Administration/Virologic/PK, and Immunogenicity Assessments  
Pretreatment medications – 1 hour (±5  min) 
prior to start of infusion 16   X           
VIS410/placebo infusion [ADDRESS_820811] a follow -up phone call in the evening of the dosing day to ensure subjects’ safety and well -being . In addition, between clinic visits up to Day 7 (e.g., 
Days 2, 4 and 6), subjects will receive a follow -up telephone call to ensure compliance with FluP RO Influenza Symptom Questionnaire  and review any new or w orsening 
signs or symptoms.  
3 Subjects who terminate the study early will return to the clinical site within 14 days after discontinuation for safety assessments. See Section 8.2  f or discharge procedure in 
case of early termination. All other subjects will return for a final follow -up visit at Day 100 ±7 days.  
4 Single nasopharyngeal swab will be obtained from one nostril.  
5 Safety Assessments may be  performed at another time, if considered needed at the Investigator’s discretion. In case unexpected symptoms are noticed in subjects, additional 
safety assessments might be performed . 
[ADDRESS_820812] in supi[INVESTIGATOR_617981]. Any significant elevation of QTc>500  msec/min should trigger repeat confirmation in triplicate.  
[ADDRESS_820813] is in the clinic.  
8 Only if screening and baseline are not on the same day.  
9 Body temperature  will be measured twice daily from Days 1 through 10 (inclusive) and then once at each follow -up visit. Self -measurement wi ll be done by [CONTACT_618034].  
10 A targeted physical exam may be performed at the Investigator’s or his/her designee’s discretion . 
[ADDRESS_820814] of tests in Appendix 1. 
14 FluPRO questionnaire will be completed at home between clinic visits through Day 10 (inclusive) . 
[ADDRESS_820815]  2 hours after completing the infusion of VIS410 to allow monitoring for possible hypersensitivity reactions. VIS410 
will be administered over 2 h ours. Infusion time can be extended at discretion of the Investigator up to 4 hours based on local infusion- related sy mptoms . If any serious 
systemic reactions occur, the infusion of VIS410 can be slowed or stopped at the discretion of the Investigator.  
18 Within 1 hour prior to VIS410 administration.  
Visterra Inc.
VIS410-202 Clinical Study Report
Page 18 of 75
19 Sample collected within 30 minutes after completing the infusion of VI S410/placebo.  
20 Nasopharyngeal swabs will be obtained from both nostrils (1 swab per nostril) . 
[ADDRESS_820816] presents with or reports influenza- like illness, additional swabs (1 swab per nostril) sho uld be taken (see Section  7.1.5 ). 
Visterra Inc.
VIS410-[ADDRESS_820817]  
AUC  Area under the curve  
AUC 0-∞ Area under the concentration -time curve extrapolated to infinity  
AUC 0-last Area under the concentration -time curve from time [ADDRESS_820818] level  
NSAID  Non-steroidal anti -inflammatory drug  
PK Pharmacokinetic  
PO Oral (by [CONTACT_1966])  
qRT-PCR  Quantitative reverse transcriptase polymerase chain reaction  
SAE  Serious adverse event  
SAP Statistical analysis plan  
SBP Systolic blood pressure  
S[LOCATION_003]R  Suspected unexpected serious adverse reaction  
t½ Elimination half -life  
TCID [ADDRESS_820819]  
 
Visterra Inc.
VIS410-202 Clinical Study Report
Page 21 of 75
1. INTRODUCTION 
1.1 BACKGROUND INFORMATION  
Severe influenza disease is a common occurrence each season, especially in high -risk groups 
such as young children, older adults, patients with pulmonary conditions, inflammatory 
conditions, malignancies, and pregnant women [ 1,2]. Despi[INVESTIGATOR_617982] h 
neuraminidase inhibitors, including oseltamivir (Tamiflu®; [COMPANY_002]; oral), zanamivir 
(Relenza®; GlaxoSmithKline; inhaled) , and peramivir (Rapi[INVESTIGATOR_52109]™; Biocryst; IV), 10%- 44% 
of hospi[INVESTIGATOR_617983] 25%-50% of these patients die. In the [LOCATION_002] , it is estimated that more than 200,000 patients are hospi[INVESTIGATOR_617984], with up to 48,000 deaths per year [
3]. 
The therapeutic use of passive polyclonal antibodies to prevent viral infections, including hepatitis B, varicella, cytomegalovirus, rabies, and respi[INVESTIGATOR_617985]. More recently, monoclonal antibodies for viral infections have been developed, including palivizumab (Synagis
®), a Food and Drug Administration- licensed treatment for 
the prevention of respi[INVESTIGATOR_227235]. 
Visterra has developed a novel approach to antibody discovery whereby [CONTACT_618035][INVESTIGATOR_617986]. Using this approach, VIS410, a broad spectrum human immunoglobulin G1 (IgG1) monoclonal antibody with demonstrated efficacy against both Group 1 (including H1 and H5) and Group 2 (including H3 and H7) influenza strains, in both treatment and prevention models of influenza, was developed. Visterra intends to develop this product for treatment of influenza A, specifically in severely ill hospi[INVESTIGATOR_9643].  
This study will provide the first indications of safety  and tolerability  of VIS410 in subjects 
infected  with uncomplicated seasonal influenza A . Efficacy as measured by [CONTACT_618036].  
1.2 NONCLINICAL STUDIES  
Pharmacology, Pharmacokinetics, and Metabolism 
VIS410 is a human IgG1 monoclonal antibody with a high sequence homology to human germ line sequences. VIS410 broadly neutralizes influenza A strains in vitro , with 
half-maximal inhibitory concentration values of approximately 0.1-11 μg/mL. Mechanistic 
studies indicate that VIS410 inhibits hemagglutinin ( HA)- mediated cell membrane fusion, 
thus preventing viral replication. 
In vivo studies have demonstrated that VIS410 administered to mice in prevention and treatment models of influenza, at doses between 1 and 20 mg/kg (either [ADDRESS_820820]- exposure) can protect mice challenged with influenza A 
strains (influenza A/Puerto Rico/8/1934 [H1N1], influenza A/Victoria/3/1975 [H3N2], and influenza A/Vietnam/1203/2004 [H5N1]). Additionally, in vivo studies in ferrets have demonstrated that treatment with VIS410 can reduce the transmission of influenza pH1N1 via 
Visterra Inc.
VIS410-[ADDRESS_820821] a newly emerging highly pathogenic H7N9 (A/Anhui/1/2013) strain of influenza in a severe Dilute Brown Non-Agouti (DBA) mouse model [
4]. 
Toxicology 
In a cynomolgus monkey Good Laboratory Practice (GLP) t oxicity/toxicokinetics study, 
4 IV doses of VIS410 were administered over a 28 -day period at 5, 50, and 250 mg/kg with 
no clinically significant findings. Based on this GLP study, the no-observed- adverse- effect 
level ( NOAEL) was considered to be 250 mg/kg and the half -life ( t1/2) of VIS410 was 
determined to be 8–9 days. 
In the cynomolgus monkey toxicology study, VIS410 was administered as an IV infusion over 10 minutes and no infusion reactions were observed.  
In a mouse GLP toxicity/toxicokinetics study (VIS 410 IV 4 doses at 5, 50 and 250 mg/kg, 
infused over 14 days to 384 mice), 14 mice (3.6%) died 1-2 hours after Day 14 dosing in the 5 and 50 mg/kg dose groups. This  was likely  due to an expected immunogenic response in 
mice , as VIS410 is a human antibody, and not a toxic response. The NOAEL was considered 
to be 250 mg/k g. 
In vitro tissue cross-reactivity studies of VIS410 with normal human tissues, cynomolgus monkey tissues, and cluster of differentiation 1 (CD-1) mouse tissues showed VIS410 to be broadly cross -reactive.  VIS410 staining of membrane was limited to cells within the 
surface/mucosal epi[INVESTIGATOR_617987], small intestine, and fallopi[INVESTIGATOR_8916]. Of note, staining was not observed in vivo, in tissues from toxicology studies in monkeys or mice when  assessed by 
[CONTACT_618037]- sacrifice.  
The lack of toxicity  in the in vivo cynomolgus monkey and mouse toxicology studies 
suggests that the cross- reactivity findings were of little toxicological significance.  
An in vitro soluble cytokine release assay performed using human whole blood at VIS410 concentrations that encompass the expected concentrations of VIS410 in human blood when administered as IV doses of 2 to 50 mg/kg, did not stimulate any acute or sustained release of any pro -inflammatory cytokines . 
1.3 CLINICAL STUDIES  
Phase 1  (VIS -C001). In a Phase 1 study (VIS -C001), a total of 30 healthy volunteers 
received a single, 120 -minute IV infusion of 2, 5, 15, 30, or 50 mg/kg of VIS410 (200 mL 
volume) (6 subjects per cohort) and 11 subjects received a single, 120-minute IV infusion of placebo (sodium chloride 0.9%; 200 mL volume). 
The PK and safety data are presented below.  
Pharmacokinetics 
PK profiles of the serum and nasopharyngeal samples demonstrated that VIS410 exposure was approximately proportional to the dose administered with  a mean serum t
1/2 of 12.9 days. 
This t 1/2 is within the expected range for the IgG1 molecules. I n addition, the 13- day t 1/2 
Visterra Inc.
VIS410-202 Clinical Study Report
Page 23 of 75
supports the single dosing of VIS410, as the circulating levels should be sufficiently high 
during the normal course of an influenza infection in hospi[INVESTIGATOR_9643]  (5–14 days). The 
maximum concentration ( Cmax) values in the serum for the 30 and 50 mg/kg cohorts were 
980 and 1316 µg/mL, respectively. 
Nasopharyngeal swabs were taken from the 15, 30, and 50 mg/kg cohorts for upper respi[INVESTIGATOR_617988] . The nasopharyngeal PK profiles were approximately dose 
proportional. M ean nasal C
max values at the 30 and 50 mg/kg dose levels were 20.0 and 
25.3 µg/mL, respectively . 
Safety 
Overall, VIS410 was generally safe and well tolerated at all dose levels  studied. 
Treatment -emergent adverse events ( TEAEs) were reported for 20/30 (66.7%) subjects 
receiving VIS410 and 7/11 (63.6%) subjects receiving placebo. There were no drug- related 
serious adverse events (SAEs), no drug-related discontinuations, and no infusion- related 
reactions such as anaphylaxis or injection site reactions.  
Notable adverse events ( AEs) included one unrelated SAE of leukopenia and esophagitis 
secondary to primary HSV -[ADDRESS_820822] (VIS410, 30 mg/kg cohort). This SAE 
resolved and the subject is doing well. Another unrelated SAE of acute appendicitis was also reported (placebo cohort).  
The most common AEs observed were diarrhea (10/41, 24.4%) and headache (8/41, 19.5%). All diarrheal or loose stool AEs were observed in the VIS410- treated subjects and were 
usually mild to moderate, started ~2 –4 hours after dosing, were transient and resolved 
spontaneously within 24 hours after dosing with no associated dehydration. The gastrointestinal (GI) events were dose proportional and the majority  of the AEs were 
observed at the highest dose tested (50 mg/kg). None of the GI events were associated with a 
systemic allergic reaction or elevation in liver or biliary laboratory values.  Mean hematology, 
serum chemistry, and urinalysis results were withi n the normal limits and the mean values 
and changes from baseline were similar across the treatment groups and placebo. Overall, mean vital sign measurements observed after dosing were similar to those observed at baseline. Mean changes from baseline were also similar across VIS410 dose levels, and no apparent treatment - or dose -related trends were observed.  
The anti -drug antibody ( ADA) data demonstrated a low level of positive ADA in 4 out of 
30 subjects receiving VIS410 ( Table 2 ). The subjects with positive ADA did not demonstrate 
any impact on their PK profile.  
Visterra Inc.
VIS410-202 Clinical Study Report
Page 24 of 75
Table 2. Study VIS -C001 ADA Data  
Cohort Dose  
(mg/kg)  No. of Confirmed  
ADA Positive  Pre-Infusion  
Titer  Confirmed  
Day Positive  
Titer  
2 0/6 None detected  NA None detected  
5 3/6 None detected  120 titer 10  
None detected  14 titer 10  
120 titer 40  
None detected  120 titer 40  
15 1/6 None detected  120 titer 40 
30 0/6 None detected  NA None detected  
50 0/6 None detected  NA None detected  
 
Phase 2a Challenge Study  (VIS410-201). Study VIS410-201, “A Phase 2a Randomized, 
Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Antiviral 
Activity of a Single Intravenous Dose of VIS410 in Healthy Subjects after a Viral Inoculation with Influenza A (H1N1),” was  conducted at a single site in Antwerpen, Belgium by  [CONTACT_618038]. Briefly, 24 hours after inoculation with a 10
6 tissue culture infective dose 
(TCID) of naturally attenuated influenza A (H1N1) virus [ 7], subjects receive a single IV 
administration of VIS410 (2300 mg fixed dose, equivalent of 30 mg/kg) or placebo (7:5 randomization to VIS410:placebo). Subjects were quarantined [ADDRESS_820823]-inoculation 
and discharged thereafter. 
A total of 46 subjects were treated with VIS410 (n=33) or placebo (n=13) across [ADDRESS_820824] 3  cohorts was conducted to 
evaluate the safety and efficacy of the 2300 mg VIS410 dose and to determine whether dose escalation was appropriat e. The distribution of subjects is presented in 
Table 3 . 
Table 3. Distribution of Subjects  
Treatment  No. Dosed  Per Protocol*  No. Infected**  
Placebo  13 9 7 
VIS410 (2300 mg)  18 16 13 
Total  31 25 20 
HAI = hemagglutinin inhibition assay positive seroconversion at Day 14 or 28. 
*Subjects with HAI >10 at baseline excluded per inclusion/exclusion criteria. 
**Infected subjects who are either polymerase chain reaction positive or HAI positive . 
 
Based on the preliminary results , VIS410 [ADDRESS_820825] with a 7 6% and 91% reduction in nasopharyngeal viral AUC by 
[CONTACT_618039].
VIS410-202 Clinical Study Report
Page 25 of 75
quantitative reverse transcriptase polymerase chain reaction  (qRT- PCR) and half -maximal 
tissue culture infective dose  (TCID 50) compared  to placebo ( Table 4 ).  
Table 4. Viral Load and AUC Data  
Viral Measure  Placebo  
(N=7)  VIS410 
(N=13)  Reduction  
(%) p Value*  
Median Viral AUC TCID 50 (log 10 X hours)  546 45 92 0.019  
Median Viral AUC  qPCR (log 10 X hours)  1031  235 77 0.024  
Median Peak Viral Load TCID 50 (log 10) 5.0 2.7 2.2 0.009  
Median Peak Viral Load qPCR (log 10) 7.1 5.6 1.5 0.043  
*Calculated with Mann -Whitney U Test.  
 
In addition, analysis of the symptoms data demonstrated a trend in respi[INVESTIGATOR_617989]. Although this study was not powered to detect a statistical difference in symptom relief, a 2-day reduction in resolution of upper 
respi[INVESTIGATOR_617990]410 [ADDRESS_820826] cohort, 7 subjects received 2300 mg of VIS410 while 5 subjects received placebo. Moderate to severe crampi[INVESTIGATOR_007], loose stool and/or diarrhea were reported in [ADDRESS_820827] symptoms were observed either during the infusion or within 30 minutes of the end of infusion and resolved within ~12 hours. Given the association with infusion, these AEs were all considered possibly 
related to the study drug. In subsequent cohorts, the addition of a pretreatment regiment containing diphenhydramine mitigated the GI AEs and VIS410 was generally well tolerated with a reduction in frequency and the severity of GI event s from moderate/severe to mild.  
As statistically significant efficacy was demonstrated with the [ADDRESS_820828] 3 cohorts, the protocol was amended to optimize the tolerability of VIS410. This was done by [CONTACT_618040] a nd escalating the dose of VIS410 to 4600 mg in the 
context of the virus challenge model. This portion of the study (designated as Part 2) was open label; however , virological data w ere collected to understand viral response and 
pharmacokinetics/pharmacodynamics.  
Eleven subjects were enrolled in Cohort [ADDRESS_820829] 10 mg PO (Group1) ; 4 subjects were pretreated 
with diphenhydramine 50 mg PO and ibuprofen 600 mg PO (Group 2) ; and [ADDRESS_820830] 10 mg PO  (Group 3).  
Three subjects in Groups [ADDRESS_820831] had a transient epi[INVESTIGATOR_617991] 8.3 hours after the start of infusion. All events were considered resolved within 24 hours of onset. 
Phase 1 (VIS410-102)  Study VIS410-102 is  a Phase 1, randomized, placebo-controlled study 
to evaluated safety, tolerability, and PK of a single 2300 mg and 3800 mg dose of VIS410 following administration of different pretreatment regimens . A total of 83 subjects received 
study drug (Placebo (n=12), VIS410 2300 mg (n=59), VIS410 3800 mg (n=12)). VIS410 2300 mg was evaluated at a 2-hour infusion (n=12), 4-hour infusion (n=12), 2-hour infusion following a pretreatment regimen of diphenhydramine 50 mg PO and ibuprofen 400 mg PO 60 minutes before infusion (n=12), 2-hour infusion following a pretreatment regimen of cetirizine 10 mg PO 60 minutes before infusion (n=12), and 2-hour infusion following a pretreatment regimen of diphenhydramine 50 mg PO and acetylsalicylic acid 325 mg PO 60 minutes before a 2 -hour infusion (n=11). The 3800 mg VIS410 dose was evaluated at a 
2-hour infusion following a pretreatment regimen of diphenhydramine 50 mg PO and ibuprofen 400 mg PO 60 minutes before infusion (n=12). The pretreatment regimens were selected in order to mitigate the GI  AEs observed with VIS410. This study is currently 
ongoing and a preliminary summary of safety data to date is presented below.  
To dat e there have been no reports of SAEs. One subject at the 3800 mg dose discontinued 
study drug infusion due to AEs  of nausea, vomiting, chills, and hot flashes. All events 
resolved after study drug discontinuation despi[INVESTIGATOR_617992]410. VIS410 was not associated with any signs or symptoms that are consistent with systemic allergic reactions or anaphylaxis.  Gastrointestinal events were observed at a higher 
frequency in the VIS410 treated subjects compared to Placebo. Based on the data from the 2300 mg and 3800 mg dose groups, VIS410 was associated with GI events ranging from mild to severe; however, a 2300 mg dose of VIS410 with a single- dose pretreatment regimen of 
diphenhydramine and low dose ibuprofen or acetylsalicylic acid  was associated with  a low 
rate of GI events (16.7% and 9.1%, respectively). Overall, the most commonly reported events were loose stool, diarrhea, and abdominal crampi[INVESTIGATOR_007]. Subjects who received no pretreatment regimen had the highest number of GI AEs ranging from mild to severe. The prolonged infusion of VIS410 (over 4 hours) resulted in a larger number of GI events than the 2-hour infusion (41 events in 10 subjects vs. 18 events in 6 subjects, respectively), suggesting that GI events will not be mitigated by [CONTACT_1743]. Pretreatment regimens of an antihistamine (cetirizine) or an antihistamine (diphenhydramine) plus a prostaglandin inhibitor (ibuprofen or acetylsalicylic acid ) mitigated the GI events compared with the no 
pretreatment cohorts. The rate (13  GI events in 7 subjects) and severity of events (12/13 mild) 
were slightly lower in the cetirizine group than the no pretreatment groups . The lowest rate of 
GI events with VIS410 was observed in subjects who received  the diphenhydramine plus 
acetylsalicylic acid  pretreatment regimen, with only [ADDRESS_820832] reporting mild nausea. Both events resolved spontaneously with no intervention. In addition, one (1) subject at the [ADDRESS_820833] that a pretreatment regimen is necessary to mitigate the GI events associated with VIS410; however, an antihistamine alone may not be as effective in mitigating the AEs. Addition of a prostaglandin inhibitor/non- steroidal anti- inflammatory drugs (NSAIDs) such as ibuprofen or 
acetylsalicylic acid  to an anti histamine was necessary to further reduce the frequency and 
severity of GI events. These data were consistent with previous safety data in an influenza virus challenge study where a regimen of diphenhydramine and ibuprofen mitigated the severity and or fre quency of GI AEs in 8 subjects given 2300 mg (n=4) and 4600 mg of 
VIS410 (n=4). 
For more detailed information on VIS410, refer to the current Investigator Brochure [ 5]. 
1.[ADDRESS_820834] s with severe influenza. 
1.5 RISK BENEFIT ANALYSIS  
In animal studies, single or multiple dose administrations of VIS410 were generally well tolerated at doses of up to 250 mg/kg. In the Phase 1 VIS-C001 study in  41 subjects (see 
Section  
1.3), all doses studied were generally safe and well tolerated with only mild to 
moderate loose stool or diarrhea seen at the highest doses administered (30 and 50 mg/kg). The most common AE was a mild/Grade 1 loose stool or diarrhea that was self -limiting. In 
the Phase 2a challenge study (VIS410 -201), administration of [ADDRESS_820835] also had a transient epi[INVESTIGATOR_617993]. The AEs observed to date with the projected therapeutic dose of 2300 mg were mostly GI events, were mild to moderate in intensity, resolved spontaneously with no additional intervention, and decreased in severity and frequency following pretreatment with ibuprofen and diphenhydramine. Considering the potential benefit of VIS410 in treatment of severe influenza A infection and the types and severity of AEs observed to date at the 2300 mg dose, the benefit outweighs the risk of further evaluation of VIS410 in patients with influenza A infection. 
1.5.1 Potential Risks 
As described above, some subjects  may experience crampi[INVESTIGATOR_6926]/or a transient loose stool or 
diarrhea . Animals that received VIS410 as either treatment or prophylaxis experienced 
decreased weight loss compared with vehicle/placebo- treated an imals following challenge 
with various strains of influenz a virus. In mice treated with 4  doses of VIS410 over 14 days, 
14 of 384 animals had  severe systemic hypersensitivity (anaphylaxis) with death within 
1-2 hours after the fourth dose; and ADAs w ere found in [ADDRESS_820836] as the NOAEL was 250 mg/kg but rather a consequence of immunological response in mice to a human antibody. Other human antibodies have elicite d ADA in mice without clinical problems in humans.  
Administration of VIS410, IV once weekly for 4 weeks in a non-human primate model of 
cynomolgus monkeys was well tolerated. All animals survived and there were no abnormal clinical observations suggesting distress to the animals (hypersensitivity -related or other) 
throughout the duration of the study period (including the administration or recovery periods). 
ADAs were elicited in  3 of the 42 (7%) samples  that had a reduction in titers  that were most 
likely  due to drug exposure. As with the mice, there were no findings suggesting VIS410 
toxicity in clinical, laboratory or pathology examinations.  
In an in vitro soluble cytokine release assay performed using human whole blood, VIS410 did not stimulate any dramatic or pervasive release of any pro -inflammatory cytokine (see 
Section  
1.2).  
Pharmacological class effects commonly ass ociated with marketed monoclonal antibody 
products used for treatment in humans include serious infusion reactions including anaphylaxis (see Section  
1.3). VIS410 is to be administered as a single infusion and is 
directed at an exogenous viral target . As a result,  it is considered to be of low probability that 
other SAEs such as infection risks reported for approved monoclonal antibodies directed 
against endogenous human protein targets such as immune modulating cytokines and often administered as multiple doses over a long period will be observed with VIS410.  
Visterra Inc.
VIS410-202 Clinical Study Report
Page 29 of 75
As described in Section 1.3, a single administration of VIS410 to healthy volunteers was safe 
and well  tolerated. The potential exists for subjects  to experience crampi[INVESTIGATOR_617994], 
but pretreatment with histamine antagonists  (diphenhydramine) with an NSAID  such as 
ibuprofen or acetylsalicylic acid  ameliorated the GI  effects . 
Given the potential for acute severe hypersensitivity and other adverse reactions observed 
with other monoclonal antibody therapi[INVESTIGATOR_014], subjects should be closely monitored for relevant signs and symptoms following administration of VIS410. VIS410 should only be administered when personnel and therapi[INVESTIGATOR_617995].  
1.5.2 Potential  Benefits  
Animals that received VIS410 as either treatment or prophylaxis experienced prolonged survival compared with vehicle/placebo- treated animals following challenge with various 
strains of influenza A virus. The Phase 2a challenge study demonstrated a statistically significant reduction in viral  AUC following treatment with VIS410 compared with placebo 
(Section  
1.3). 
At this time , the actual benefits of VIS410 for the treatment of influenza patients are 
unknown. However, data from a recently conducted  human challenge study in 31 healthy 
volunteers given influenza A demonstrated a statistically significant decrease in shedding of influenza virus with  a shorter duration of symptoms (2 days ) in the VIS410- treated group 
compared with  the placebo group. 
 
2. STUDY OBJECTIVES 
2.1 PRIMARY OBJECTIVE  
• Assess the safety and tolerability of a single intravenous (IV) dose of VIS410 in patients 
with uncomplicated influenza infection 
2.2 SECONDARY OBJECTIVES  
• Evaluate the efficacy of VIS410 compared with placebo on the time to alleviation of 
clinical symptoms of acute uncomplicated influenza  
• Evaluate the effect of VIS410 on severity of inf luenza infection  
• Assess the pharmacokinetics of VIS410 in serum 
• Assess the effects of VIS410 on viral shedding 
• Assess the immunogenicity of VIS410 
2.3 EXPLORATORY OBJECTIVES  
• Assess the pharmacokinetics of VIS410 from nasopharyngeal secretions  
• Assess viral isolates to determine the emergence of VIS410- resistant viruses  
• Assess correlations between virology, safety, pharmacokinetics, viral shedding , clinical 
symptoms , and other endpoints 
• Assess the anti -influenza immune response 
Visterra Inc.
VIS410-202 Clinical Study Report
Page 30 of 75
3. STUDY ENDPOINTS 
3.1 PRIMARY ENDPOINTS  
• The proportion of subjects with adverse events ( AEs) and serious adverse events ( SAEs ) 
following administration of VIS410 
• The proportion of subjects with treatment -emergent AEs ( TEAEs ) including 
hypersensitivity reaction, anaphylactic reaction , and AEs of special interest (AESIs) 
following dosing 
3.2 SECONDARY ENDPOINTS  
• The incidence, severity, and duration of signs and symptoms of influenza- like illness as 
assessed by [CONTACT_618041] a single IV dose 
of VIS410 
• Percentage of participants requiring hospi[INVESTIGATOR_617979]- related complications  
• Duration of hospi[INVESTIGATOR_617979]- related complications  
• Percentage of participants with complications of influenza  
• Percentage of participants with influenza A relapse/reinfection  
• VIS410 PK parameters (C max, tmax, AUC 0-∞, AUC 0-last, t1/2, Vd, CL) in serum  
• The difference between VIS410 and placebo treatment groups in viral AUC from 
nasopharyngeal swabs 
• The difference between VIS410 and placebo treatment groups in peak viral load and time 
to resolution of viral load from nasopharyngeal swabs 
• Titer of anti-VIS410 antibody- positive samples  
3.3 EXPLORATORY ENDPOINTS  
• PK parameters (C max, tmax, AUC 0-∞, AUC 0-last, t1/2) of VIS410 from nasopharyngeal 
secretions  
• Genotypic and phenotypic assessment to determine the emergence of VIS410- resistant 
viruses 
• Correlations between  serum and /or nasopharyngeal PK  with  viral load , clinical 
symptoms, presence of ADAs, and additional endpoints 
• Titer of anti-influenza A antibodies by [CONTACT_618017] ( HAI) in serum 
• Correlations between virology and safety parameters and/or additional parameters may be explored   
 
 
4. STUDY DESIGN 
4.1 OVERVIEW OF STUDY  DESIGN  
This is a Phase 2a randomized, double-blind, placebo-controlled study to be conducted in 
approximately 150 subjects with uncomplicated influenza. This study will include approximately  50–[ADDRESS_820837] placebo. Subjects  will be assigned randomly to receive VIS410 at a 
dose of 2000 mg (low dose) or 4000 mg (high dose) or placebo (0.9% sodium chloride) at a 
ratio of 1:1:[ADDRESS_820838] s’ safety and 
well-being . Subjects  will return for follow -up visits on Days 3 (±1 day ), 5 (±1 day), 
7 (±1  day), 14 (±3  days ), 28 (±3  days ), 56 (± 7 days ) and 100 (± 7 days) . In addition, between 
clinic visits up to Day 7 (e.g., Days 2, 4 and 6) subjects will receive a follow -up tele phone 
call to ensure compliance with FluP RO Influenza Symptom Questionnaire and review any 
new or worsening signs or symptoms. The Schedule of Assessments is presented in Table [ADDRESS_820839] (DSMB) will be established to review all  
available safety data after [ADDRESS_820840] DSMB, the 
DSMB will convene if the overall relative GI adverse event rate reaches 50% or the rate of moderate GI adverse events reaches 25%.  
A schematic overview of the study design is shown in Figure 1 . The assessments performed 
are summarized per visit in the  Time and Events Schedule . 
Figure 1. Schematic Overview of the Study  
Screening; Rapid Diagnostic Test for Influenza A  
  
If Rapid  Diagnostic T est is Influenza A -positive: Start dosing:  
2000 mg VIS410 (low dose), 4000 mg  VIS410 (high dose) or placebo 
  
In 30 subjects, DSMB review of data up to Day 5  
  
In 75 subjects, DSMB review of data up to Day 28  and 
optional interim analysis  
  
Optional i nterim analysis after all subjects completed Day 14 
 
4.2 DISCUSSION OF STUDY DESIGN  
Dose Selection  
Various methods were utilized to determine the efficacious dose of VIS410 in humans for the treatment of influenza. These methods included evaluation of doses and exposures to provide VIS410 levels which exceed in vitro susceptibility measures, including neutralization EC
50 
and binding affinity, bridging efficacious doses in preclinical species to humans based on a mg/kg dose and PK, and exploratory PK/PD analyses of serum and nasal exposure versus antivir al activity of VIS410 in a human influenza virus challenge study. VIS410 broadly 
Visterra Inc.
VIS410-202 Clinical Study Report
Page 32 of 75
neutralizes influenza A strains in vitro with EC 50 values ranging from 0.03 to 64.2 µg/mL 
(median of 3.15 µg/mL) and binds with high avidity (30 to 380 pi[INVESTIGATOR_36379]) to HA across 
Group 1 and Group 2 subtypes. VIS410 doses of approximately 2300 mg will result in C max 
serum level of 873 µg/mL, which is well above median EC 50 of 3.15 µg/mL in serum and 
nasal cavity for the duration of viral shedding. Furthermore, in preclinical animal studies, VIS410 demonstrated efficacy at doses of 20 to 30 mg/kg or less against various Group 1 and Group 2 influenza A strains with EC
50 values ranging from 0.57 to 2.4 µg/mL. Using a 
standard mg/kg conversion, these doses equate to 1500–2300 mg dose in humans (assuming a [ADDRESS_820841]). In a human influenza virus challenge study a single dose of 2300 mg  
demonstrated significant reduction in viral load area under the curve (AUC) and peak viral load compared with placebo, suggesting that doses of approximately 2300 mg may be 
efficacious in naturally occurring influenza infection. For strains with higher EC
50, doses 
greater than 2300 mg may be necessary to achieve adequate concentration at the primary site of infection. Based on th ese data, doses of 2000 and 4000 mg were selected for evaluation in 
this Phase 2a study. A dose of 4000 mg will ensure separation in VIS410 systemic exposures from the 2000 mg dose level to identify potential differences in safety and efficacy between the 2 doses. A dose level of 2000 mg provides a safety margin of approximately 9.4-fold to the nonclinical NOAEL (250 mg/kg), with the [ADDRESS_820842]. In addition, in the Phase 1 pretreatment study (VIS410-102 ) doses of 2300 and 3800 mg were well tolerated following a pretreatment 
regimen of diphenhydramine plus ibuprofen.  
Selection of Study Population 
Approximately one hundred fifty (150) subjects  will be enrolled in 3 equal arms : 
VIS410 2000 mg , VIS410  4000 mg , and  placebo. The subjects  will be carefully screened for 
eligibility.  
4.3 INCLUSION CRITERIA  
Subjects meeting all of the following criteria are eligible to participate in this study:  
1) Male and female subjects aged ≥18 years and ˂ 65 years  
2) Women should fulfil l one of the following criteria:  
a) Post- menopausal; either amenorrhea ≥12 months or follicle stimulating hormone 
>40 mIU/mL as documented in their medical history.  
b) Surgically sterile; hysterectomy, bilateral oophorectomy, or tubal ligation.  
c) Women of childbearing potential participating in heterosexual sexual relations must 
be willing to use adequate contraception from screening until [ADDRESS_820843]-infusion, per Section  
7.1.2 .  
3) Non-vasectomized (or vasectomized less than 6 months prior to dosing) male subjects 
who have a female partner of childbearing potential must use an effective birth control method (see Secti on 
7.1.2 ) when having heterosexual intercourse, from screening until 
[ADDRESS_820844]-infusion.  
4) Test positive for influenza A by [CONTACT_618042] a commercially 
available test on an adequate nasopharyngeal specimen in accordance with the manufacturer's instructions 
Visterra Inc.
VIS410-202 Clinical Study Report
Page 33 of 75
5) Presence of at least one respi[INVESTIGATOR_20321] (cough, sore throat, or nasal symptoms) of 
moderate to severe intensity, or pre sence of at least one constitutional symptom (myalgia 
[aches and pains], headache, feverishness, or fatigue) of moderate to severe intensity 
6) Onset of symptoms (time when the temperature was first measured as elevated 
[temperature of ≥ 100.4°F or ≥ 38°C], OR the time when the subject experienced at least 
one respi[INVESTIGATOR_617996]) no more than 72 hours before the start of infusion  
7) Subject is able and willing to comply with study procedures, as per protocol 
8) Subject is able and willing to give voluntary written informed consent 
 
4.4 EXCLUSION CRITERIA  
Subjects meeting any of the following criteria are excluded from participation in this study:  
1) Use of NSAIDs or antihistamines within 6 hours of study drug dosing with the exception of those used as part of the pretreatment regimen. 
2) History of intolerance or allergic response to monoclonal antibodies and/or pretreatment medications  (diphenhydramine, ibuprofen and acetylsalicylic acid ) 
3) History of receiving monoclonal antibody products within 3  months prior to enrollment in 
this study or planned administration during the study period 
4) Subjects in whom nasopharyngeal swabbing is not possible 
5) Subject weight less than (<) 45  kg 
6) Subjects with clinical history that would lead to increased risk  of influenza complications 
including but not limited to clinically significant cardiac disease, moderate to severe asthma, or other moderate to severe chronic obstructive pulmonary disease, metabolic syndrome including moderate to severe diabetes or activ e tuberculosis. 
7) History of chronic GI  disease, including bleeding, ulceration, Irritable Bowel Syndrome, 
systemic mastocytosis,  or chronic diarrhea 
8) Women who are pregnant, breast-feeding, or considering becoming pregnant.  
9) Patients with hypoxemia requiring  oxygen support. 
10) Clinical evidence of worsening of any chronic medical condition (temporally associated with the onset of symptoms of influenza) which, in the Investigator's opi[INVESTIGATOR_1649], indicates that such finding(s) could represent complications of influenza 
11) Presence of immunocompromised status due to chronic illness, previous organ transplant, or use of immunosuppressive medical therapy including systemic steroids. 
12) Presence of known human immunodeficiency virus (HIV) infection PLUS any one of the following: 
a) A CD4 count ≤ 500 cells/mm3 (CD4 count obtained within the 3 months prior to 
screening)  
b) An Acquired Immune Deficiency Syndrome- defining illness. (HIV testing required at 
screening visit for all patients with no documented HIV status within 3 months prior to screening.)  
13) Presence of known chronic hepatitis B or hepatitis C. 
14) Receipt of any dose of  antiviral therapy such as, but not limited to,  rimantadine, 
amantadine, peramivir, zanamivir, laninamivir or oseltamivir in the 7  days prior to 
screening  
Visterra Inc.
VIS410-202 Clinical Study Report
Page 34 of 75
15) Enrollment in any other investigational drug or device study, any disease or vaccine study 
within 30 days prior to Day 1 or within 5 half-lives of the investigational compound, 
whichever is longer 
16) Presence of any pre-existing illness that, in the opi[INVESTIGATOR_689], would place the subject at an unreasonably increased risk through participation in this study 
17) Subjects unable to comply with study protocol procedures and study visit schedules for whatever reason  
18) Subjects unable to take oral predose medication  
19) Known or suspected alcohol or drug abuse, that is, abuse of a level that would 
compromise the safety or cooperation of the subject in the opi[INVESTIGATOR_689] 
20) Subjects on chronic medications where the dose has not been stable for at least 3 months 
 
5. TREATMENT(S)  
Manufacturing, packaging, and labelling  of the investigational product,  VIS410, is  done 
under the responsibility of the Sponsor. 
5.[ADDRESS_820845] is  manufactured by [CONTACT_618043] (GCP).  
VIS410 is colorless to slightly yellow, clear to opalescent solution; essentially free of 
particles.  VIS410 is formulated at a concentration of 25 mg/mL in 40 mM citrate-sodium 
phosphate, 150 mM sodium chloride, and 0.025% polysorbate 80. 
The investigational product will be provided by [CONTACT_1034]. VIS410 will be supplied in Type I 20- mL glass vials containing a nominal [ADDRESS_820846] will accompany the study drug to the clinical center.  
The study drug will be labelled according to local law and regulatory requirements.  
Specific dilution procedures of the study drug will be described in detail in the dispensing protocol. 
Placebo will be a normal saline solution (0.9%) and  will be prepared  by [CONTACT_32335] . 
5.[ADDRESS_820847]  may receive premedications 120 minutes prior to IV infusion.  
Visterra Inc.
VIS410-202 Clinical Study Report
Page 35 of 75
5.3 STORAGE AND DRUG ACCOUNTABILITY  
5.3.1 Study Drug 
The Investigator (or designee) is responsible for the safe storage of all st udy drugs assigned 
to the clinical site . The investigational product should be stored in a locked, secure storage 
facility with access limited to those individuals authorized to dispense the investigational 
product, and maintained within the appropriate ra nges of temperature. All study drugs must 
be stored in the original packaging and as specified at delivery .  
The study investigational product be stored between 2 °C and 8°C and should be protected 
from light during storage at the clinical site.  
Regular temperature recordings of the study drug storage refrigerator at the clinical site 
should be performed. In case a deviation in the storage conditions should occur, the site must 
not further dispense the affe cted study drug ; instead , the Sponsor should be notif ied and will 
confirm whether or not the study drug may be further dispensed. 
The Investigator is responsible for ensuring that all study drugs received at the clinical site 
are inventoried and accounted for throughout the study.  
Study drugs should be dispensed under the supervision of the Investigator, a qualified 
member of the investigational staff, or by a hospi[INVESTIGATOR_307]/clinic pharmacist . The Investigator must 
maintain accurate records demonstrating date and amount of drugs administered to whom and by [INVESTIGATOR_412937] m. Study drugs will be supplied only to subjects  participating in the study.  
The M onitor responsible for drug accountability will periodically check the supplies of study 
drugs held by [CONTACT_618044] . 
Unused study drugs must be available for verification by [CONTACT_1034] ’s Monitor responsible 
for drug accountability during on- site monitoring visits. Any discrepancies between returned 
and expect ed returned study drugs should be explained. 
After the last visit of the last subject  in the study (LS LV), any used and unused 
investigational product will be r eturned to the Sponsor, or destroyed with the Sponsor’s 
written permission (in this case a certificate of destruction will be provided  and filed in the 
Trial Master File ). 
Hazardous materials such as used needles  and syringes should be disposed of immediately in 
a safe manner and therefore will not be retained  for drug accountability purposes. 
5.4 DOSE AND ADMINISTRATION  
The site’s unblinded pharmacist or properly trained designee will prepare the VIS410 or placebo according to the instructions in the pharmacy manual. The required amount of VIS410 to be dosed (2000 mg or 4000 mg ) will be diluted with normal saline up to a total 
volume of [ADDRESS_820848] will be administered IV at a rate of 100 mL/h, over 2 hours. After 200 mL of the diluted dose has been administered (the infusion bag is empty), the infusion line will be flushed with [ADDRESS_820849] dose is delivered . The infusion time may be longer at the Investigator’s discretion based on local 
infusion site -related symptoms  up to a maximum of [ADDRESS_820850] 2 hours at the 
infusion center and discharged if considered safe by [CONTACT_093]. Prior to discharge, all subjects will be counseled on the potential GI AEs and management of the se events . 
Pretreatment: Subjects  will be given a pretreatment regimen of diphenhydramine [ADDRESS_820851] has any history of delayed gastric emptying, including premenstruation syndrome or menstruation, they may receive premedications 120 minutes  
prior to IV infusion. In subjects with underlying renal impairment, caution should be taken with use of NSAIDs ( ibuprofen or acetylsalicylic acid ). Subjects with renal impairment must 
be adequately hydrated prior to administration of the pretreatment regimen and renal function should be monitored to ensure subject safety.  
5.5 TREATMENT COMPLIANCE  
To ensure treatment compliance, all study drug infusions will be supervised by [CONTACT_21438]/her designee.  
5.[ADDRESS_820852] DSMB, the DSMB will convene if the overall relative GI 
adverse event rate reaches 50% or the rate of moderate GI adverse events reaches 25%. Study enrollment and dosing will continue whilst the DSMB  evaluates data.   
Assessment of subject safety will be determined from vital sign measurements  ECGs , 
physical examinations, hematology, chemistry and urinalysis laboratory testing, use of concomitant medications, and review of AEs should they occur.  
If req uested by [CONTACT_4318] , additional meetings can be scheduled to follow up further safety 
data during the study. The DSMB  will review the safety data in detail. If any safety concern 
is raised by [CONTACT_4318] , treatment  can be temporarily or permanently halted. 
Doses may be adjusted downward at the discretion of the DSMB based on review of safety 
data including GI adverse events. Further details will be described in a separate D SMB 
charter.  
 
Visterra Inc.
VIS410-[ADDRESS_820853] be recorded  in the electronic data capture ( EDC ) system (name [CONTACT_618081]). I ntake of concomitant medication(s) will be monitored 
continuously from signing of Informed Consent Form ( ICF) until the last study  visit. 
6.[ADDRESS_820854] has taken within 14 days of study drug administration will be 
documented in the EDC. Influenza vaccination within the prior 6 months will also be documented in the EDC. The use of over the counter, symptom-modifying drugs such as NSAIDS, antihistamines, or pseudoephedrine are prohibited in the 6 hours prior to dosing of study drug with the exception of the pretreatment medications.  
6.2 PERMITTED CONCOMITANT THERAPI[INVESTIGATOR_617997] ( paracetamol ), as per license, is allowed during 
the study. As the impact of VIS410 on symptoms of influenza is a secondary objective of this 
study, the use of acetaminophen ( paracetamol ) should be minimized. 
Chronic medications not listed in excluded concomitant medications, are permitted where the dose has been stable for at least 3 months prior to screening. 
The use of symptom-modifying drugs such as NSAIDS, antihistamines, or pseudoephedrine are discouraged  and in case a symptom modifying agent is needed, 
paracetamol/acetaminophen should be encouraged as the drug of choice.  
In case of clinical worsening of influenza- related  symptoms recorded at baseline or 
development of two new influenza- related  symptoms [ADDRESS_820855] safety and 
well-being.   
6.3 EXCLUDED CONCOMITANT MEDICATIONS  
Consistent with exclusion criteria , the use of antivirals should be excluded except as outlined 
in Section  6.2. Excluded antiviral  medications include , but are not limited to: rimantadine, 
amantadine, peramivir, zanamivir, laninamivir or oseltamivir.  
Use of antibiotics is discouraged unless there is a documented or suspected bacterial infection. 
 
Visterra Inc.
VIS410-[ADDRESS_820856] ’s 
last visit.  
7.1 TIMING OF ASSESSMENTS  
If the following assessments are planned at the same time, the order of assessments should be 
as follows: 
1) Influenza Patient Reported Outcomes questionnaire  
2) Vital signs  
3) Nasopharyngeal swab  
4) Blood s ampling  
7.1.[ADDRESS_820857]-infusion. For the purposes of this study, women who do not meet one of the following criteria listed below are considered to be physiologically capable of becoming pregnant and are, therefore, defined as women of childbearing potential:  
o Non-childbearing potential: 
o Post-menopausal: ≥ 12 months of natural (spontaneous) amenorrhea or 
o 6 weeks after surg ical bilateral oophorectomy with or without hysterectomy or  
o follicle stimulating hormone > 40 mIU/mL  
o hysterectomy  
o bilateral tubal ligation   
Women of childbearing potential and all male subjects participating in heterosexual sexual relations must be willing to practice effective contraception from screening until [ADDRESS_820858]-infusion. For the purposes of the study, highly effective contraception is defined as : 
o Combination of an established form of hormonal contraception (oral, injected, or 
implanted) or an intrauterine device or intrauterine system  
 
Visterra Inc.
VIS410-202 Clinical Study Report
Page 39 of 75
and 
 
o A physical barrier method of contraception with use of a spermicide such as condom 
or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream suppository. The use of barrier contraceptives should always be supplemented with the use of a spermicide, unless not available in a country 
 
o Male vasectomy with negative semen analysis documentation. The use of contraception does not apply if the male partner has been vasectomized at least 6 months prior to dosing  
 
o Complete abstinence can be considered an acceptable method of contraception at the 
discretion of the Investigator. Periodic abstinence (e.g., calendar, ovulation, 
symptothermal, or post-ovulation methods) and withdrawal are not considered acceptable methods of contraception  
 
The combination of 2 barrier methods, periodic abstinence (e.g., calendar, ovulation, 
symptothermal, or post-ovulation methods), and withdrawal are not considered acceptable 
methods of contraception.  
Pregnancy reporting is described in Section  10.8. 
7.1.[ADDRESS_820859] has fulfilled the entry criteria, he/she will be assigned a unique identifier.  The 
site will randomize the subject using the Interactive Web Response System ( IWRS ).  
7.1.[ADDRESS_820860] for influenza. Flu-positive subjects will then be given a full explanation of the nature of the study and written informed consent (approved by [CONTACT_1579]) will be obtained according to local requirements before any study -related 
assessment will be carried out.   
At screening, subjects will be requested to attend the clinical center to have assessments performed as described in the  
Time and Events Schedule .  
All results from the screening procedure s required  to evaluate eligibility  must be available 
prior to drug infusion on Day 1. Any abnormal assessment at the screening visit will be assessed according to its clinical relevance, and if found relevant, the subject will not be included in the study.  
On Day [ADDRESS_820861] a follow -up phone call in the evening of the 
dosing day to ensure safety and well -being .  
Visterra Inc.
VIS410-202 Clinical Study Report
Page 40 of 75
Follow-up Clinic Visits and Telephone Calls :  
All subjects will be asked to come back to the clinical center for follow -up visits on Day  3 
(±1 day), 5 (±1 day), 7 (±1 day), 14 (±3 days), 28 (±3  days), 56 (±7 days), and Day 100 
(±7 days). In order to provide some flexibility for the subjects regarding the site visits and to 
maintain the integrity of the study design, a time window is permitted for the follow -up visits 
in case of time  conflict or unforeseen circumstances.  
In addition, between clinic visits up to Day 7 (e.g., Days 2, 4 and 6) subjects will receive a 
follow-up tele phone call to ensure compliance with FluP RO Influenza Symptom 
Questionnaire and review any new or worsening signs or symptoms.  
Subjects who terminate the study before completion  of the scheduled study procedures for 
any reason (AE, withdrawal of consent, etc.) should be asked to complete study assessments (including safety) prior to withdrawal if possible. S ubject s who withdraw for safety reasons 
should come for a s afety follow -up visit as soon as possible within 14 days after 
discontinuation. 
7.1.5 Virological Assessments  
The virological laboratory a ssessments are:  
• At screening, a s ingle n asopharyngeal swab will be obtained from one nostril for the 
rapid test .  
• A nasopharyngea l swab  will be collected from each nostril as described in the 
schedule of assessments and laboratory manual. These swabs will be sent to a central 
virology laboratory for processing into appropriate aliquots for virology and analysis as detailed in Sections  
7.2.1 , 7.3.1 , 7.4, and 7.5.  
• Further details on sample collection, processing, shipment, and storage will be 
described in the laboratory manual.  
• Virology samples taken from all subjects  may be infectious and will be classified as 
“diagnostic specimens” for dispatch purposes. 
• The Investigator may also perform additional tests in the local laboratory consistent with standard of care for the illness being treated. 
7.1.[ADDRESS_820862] the trial center if they exhibit worsening symptoms or 
new epi[INVESTIGATOR_617998]-like illness so that they may be monitored and asked to return to the site for additional assessments (safety, nasopharyngeal swabbing) at the Investigator’s 
discretion . Findings made during unscheduled visits should be reported in the EDC  system 
and should be reported in the source documents. 
Visterra Inc.
VIS410-[ADDRESS_820863] serum separator tubes and will be immediately chilled (ice bath).  Further 
procedures for sample collection, shipment, processing, and storage will be described  in the 
laboratory manual.  
Nasopharyngeal swabs for determination of VIS410 concentration from nasopharyngeal 
secretions will be taken at the time points defined in the  Time and Events Schedule . Further  
details on sample  collection, processing, shipment, and storage will be described in the 
laboratory manual.  
7.2.[ADDRESS_820864] non-compartmental approaches using Phoenix WinNonlin (Pharsight Corporation, Princeton, NJ , [LOCATION_003]; Version 6.3 or higher) will be used to estimate PK parame ters in serum 
and from nasopharyngeal secretions as described below.  
The following PK parameters will be determined for VIS410 in serum and/or from nasopharyngeal secretions : 
• Cmax: maximum observed concentration 
• Tmax: time  of C max 
• AUC 0-∞: area under the concentration- time curve from time 0 extrapolated to infinity  
• AUC 0-last: area under the concentration -time curve from time [ADDRESS_820865] measurable 
concentration  
• t1/2: terminal elimination half -life 
• CL: total clearance  (serum  only) 
• Vd: volume of distribution  (serum  only) 
• Ratio of nasal :serum AUC  
Additional PK parameters may be determined as appropriate. PK data from this study will be also analyzed by [CONTACT_618045].  
Visterra Inc.
VIS410-[ADDRESS_820866]  at the time points indicated in the 
Time and Events Schedule . 
Unsolicited  (i.e., not collected via the FluPRO  questionnaire) signs and symptoms will be 
collected and scored via a targeted physical exam that will be performed by [CONTACT_618046] . Timing of this assessment is provided in the  Time and Events Schedule  and is to 
be performed at the discretion of the Investigator or designee.  
Body  temperature will also be measured.  Fever is defined as a body temperature ≥38°C. 
The solicited and unsolicited signs and symptoms of influenza will not be reported as AEs as 
these constitute an endpoint of the study and will be recorded as such, unless a situation arises w hereby [CONTACT_618047][INVESTIGATOR_617999]. 
7.[ADDRESS_820867] of ADA on neutralization in accor dance 
with local regulations.  
7.4.2 Anti-Influenza  Antibody Response  
Venous serum samples (5 mL) will be collected to determine anti- influenza antibody titers 
according to the time points defined in the  Time and Events Schedule  and according to the 
instructions provided in the laboratory manual . Anti -influenza antibody titers will be 
determined by [CONTACT_618048].  
Visterra Inc.
VIS410-[ADDRESS_820868] any 
change occurring during t he study he/she considers to be clinically relevant in the EDC  
system. Laboratory values outside the normal range will be flagged and their clinical 
relevance will be assessed by [CONTACT_737].  
Visterra Inc.
VIS410-202 Clinical Study Report
CONFIDENTIAL
Page 44 of 75
7.6.3 Vital Signs  
Vital sign parameters will be assessed after 5  minutes in supi[INVESTIGATOR_618000] . The vital sign parameters that will be assessed are 
supi[INVESTIGATOR_9219] ( SBP), diastolic blood pressure ( DBP ), heart rate, respi[INVESTIGATOR_618001]. 
Body temperature will be assessed using a thermometer  preferably at approximately the same 
times of day for each measurement .  
Any change from baseline in vital sign  values  occurring during the study that is considered  to 
be clinically relevant by [CONTACT_618049]. 
7.6.[ADDRESS_820869] at the time points indicated in 
the Time and Events Schedule . The ECG parameters assessed are heart rate, PR interval, 
QRS interval, QT interval. Values for QT corrected for heart rate (QTc) will be derived. QTc 
corrected according to Fridericia (QTcF) [ 6] will be the primary correction parameter . QTc 
parameters can be calculated subsequently if not immediately available at the site. If a subject has an elevated QTc >500 msec/min on assessment then repeat assessments in triplicate should be performed for confirmation. 
Any change from baseline in ECG  values occurring during the study that is considered to be 
clinically relevant by [CONTACT_618049]. 
7.6.5 Physical Examination  
A complete p hysical examination will be performed at the time points indicated in the Time 
and Events Schedule . A targeted physical exam may be performed at the Investigator ’s or 
his/her designee’s discretion at the time points indicated in the  Time and Events Schedule . 
Physical examination at screening will include height and weight. To obtain the actual body weight, subjects must be weighed lightly clothed at screening. The height should be measured barefoot. 
Any change in physical examination occurring during the study that is considered to be 
clinically relevant by [CONTACT_618050] . 
7.[ADDRESS_820870] ’s safety  (i.e., an AE) , additional blood samples (up 
to 50 mL) and/or urine samples may be taken at the discretion of the Investigator per standard of care. 
7.[ADDRESS_820871], and are generally recognized as 
reliable, accurate, and relevant.  
Visterra Inc.
VIS410-202 Clinical Study Report
CONFIDENTIAL
Page 45 of 75
8. STUDY TERMINATION/CO MPLETION  
8.[ADDRESS_820872] 
follow-up visit (Day 100). 
8.[ADDRESS_820873] of the Investigator or Sponsor (or designee). Each subject withdrawn from the study after receipt of any amount of study drug is to be encouraged to undergo as many post-study drug administration assessments as possible at the time of withdrawal.  The reason for a subject’s withdrawal 
should be recorded on the appropriate page(s) of the e lectronic C ase Report F orm. Reasons 
for withdrawal from the study may include, but are not limited to, the following: 
• Withdrawal of consent; 
• Significant subject noncompliance, defined as refusal or inability to adhere to the 
protocol requirements, e.g., subject restrictions and follow-up visit schedule;  
• The Investigator determines that it is in the best interest of the subject to withdraw 
from study participation  
If a subject  is withdrawn from the study as a result of a product- related SAE (for details on 
AE reporting see Section  10), notify the S tudy Monitor and Sponsor within [ADDRESS_820874] until 
satisfactory health has returned.  
Subjects who terminate the study before completion of the scheduled study procedures for any reason (AE, withdrawal of consent, etc.) should be asked to complete study assessments (including safety) prior to withdrawal if possible. Subjects who withdraw for safety reasons should come for a safety follow -up visit within [ADDRESS_820875] . 
8.3 STOPPI[INVESTIGATOR_618002] a DSMB  (see Section 5.6). Based upon any safety assessments 
and after mutual agreement with the Investigator (or designee) and the Sponsor, the study 
may be temporarily or permanently halted.  Study enrollment and dosing will continue whilst 
the DSMB evaluates data.  
Dosing will temporarily pause whilst the DSMB meet s if: 
• a drug -related or unexpected drug -related  SAE occurs in at least [ADDRESS_820876],  
Visterra Inc.
VIS410-202 Clinical Study Report
CONFIDENTIAL
Page 46 of 75
• 25% or more subjects have GI  symptoms  of Grade [ADDRESS_820877] Research Organization ( CRO ) and site study 
personnel and Visterra personnel will not be aware of which treatment (active study drug or 
placebo)  the subjects have been given. Subjects will not be aware of which treatment they 
have been administered. 
Subjects will be randomized 1:1:[ADDRESS_820878] be used sequentially to ensure an overall balance; no randomization number can be skipped. Allocation of each subject to a given treatment sequence will be described in a randomization list prepared by [CONTACT_618048]. The randomization will be balanced using randomly permuted blocks across the treatment groups.  
The randomization list will not be a vailable to the subj ects, Investigators, (blinded) monitors, 
or employees of the clinical center involved in the management of the study before unblinding of the data, unless in case of emergency. The Sponsor’s clinical team will also be blinded during the study as they will not have direct access to the randomization list. The CRO  performing data management and statistical activities will receive a copy of the 
randomization list during database lock. Other team members will not have access to any data 
that could lead to unblinding.  
Unblinding of the individual subject’s treatment by [CONTACT_618051]'s study treatment is necessary for clinical management. In such cases, the Investigator must first 
attempt to contact [CONTACT_618052] (contact [CONTACT_618053] a separate document), to discuss and agree to the need for unblinding to occur. The Medical Monitor or designee will answer calls [ADDRESS_820879]'s treatment assignment has been unblinded, t he Medical Monitor and study 
coordinator should be notified within 24 hours of unblinding of the treatment. Information 
relating to unblinding (e.g., reason and date) shall be clearly recorded in the subject’s study 
file, as part of relevant standard operating procedures. In addition, the Investigator should 
consider whether the clinical event prompting unblinding should be considered an SAE, according to the regulatory  definitions or criteria for SAEs, and if so, submit an SAE report to 
Visterra  or designee.  
Visterra  or designee will also unblind any SAE reports that  are serious, unexpected, and 
considered to be related to the study drug, in accordance with safety reporting guidance and regulations. 
9.3 STATISTICAL ANALY SIS 
VIS410 endpoints  will compare aggregated VIS410 data as well as different dose levels of 
VIS410 to the placebo arm. Further details of the statistical methodology will be described in the statistical anal ysis plan (SAP).  
9.3.1 Analysis Populations 
The following analysis populations will be defined for the study: 
Intent -to-Treat (ITT) : All subjects randomized to treatment.  
Modified Intent -to-Treat (mITT) : All subjects who  receive IV study drug and are 
confirmed influenza A positive by a molecular test at the central virological lab oratory. 
Safety Population:  All ITT subjects who received IV study drug . 
PK Population (PK) : All subjects who received IV study drug with at least [ADDRESS_820880] Sample  
Summary statistics will be provided per treatment group for demographic (e.g., age, height, weight, Body Mass Index , race, gender) and other initial subject  characteristics (physical 
examination, medica l history, concomitant diseases) will be provided per treatment group and 
for the total group. The ITT population will be used for the summaries. 
Prior and concomitant medications will be coded using the World Health Organization  Drug 
Dictionary.  
9.3.[ADDRESS_820881] non-compartmental approaches using Phoenix WinNonlin (Pharsight Corporation, Princeton, NJ , [LOCATION_003]; Version 6.3 or higher) will be used to estimate the PK parameters in 
serum and nasopharyngeal secretions (see Section  
7.2.3 ) described below. All calculations 
will use the actual times recorded in the EDC  system for dosing and sampling. Individual and 
mean (±SD) or median concentrations versus time profiles will be plotted by [CONTACT_618018]. Additional plots and PK parameters may be generated as appropriate. The PK population will be used for the summaries. 
Visterra Inc.
VIS410-[ADDRESS_820882] deviations, CV, medians and ranges, as appropriate. Additional analyses and summaries may be generated as appropriate.  
The following PK parameters will be determined for VIS410 in serum: 
• Cmax: maximum observed serum concentration 
• Tmax: time  of C max 
• AUC 0-∞: area under the serum concentration -time curve from time 0 extrapolated to 
infinity  
• AUC 0-last: area under the serum concentration- time curve from time [ADDRESS_820883] 
measurable concentration  
• t1/2: terminal elimination half -life 
• CL: total clearance  
• Vd: volume of distribution  
PK data from this study will be also analyzed by [CONTACT_618054]. 
Nasopharyngeal Secretion Pharmacokinetics 
Nasopharyngeal secretion  concentrations and the computed PK parameters will be listed by 
[CONTACT_618019]410. Summary statistics of nasopharyngeal secretion concentrations and PK 
parameters w ill be presented including means, geometric means, standard deviations, CV, 
medians and ranges, as appropriate. Additional analyses and summaries may be generated as appropriate. 
The following PK parameters will be determined for VIS410 from nasopharyngeal secretions : 
• Cmax: maximum concentration observed from nasopharyngeal secretion s  
• Tmax: time of C max 
• AUC 0-∞: area under the nasopharyngeal secretion concentration -time curve from 
time 0 extrapolated to infinity 
• AUC 0-last: area under the nasopharyngeal secretion concentration -time curve from 
time [ADDRESS_820884] measurable concentration  
• t1/2: terminal elimination half -life 
• Ratio of nasal:serum  AUC  
Additional PK parameters may be determined as appropriate. 
9.3.4 Viral Shedding  
Additional sensitivit y analysis may be conducted excluding subjects that received 
concomitant antiviral therapy during the course of the study.  
• One-way analysis of variance (ANOVA) (with treatment group as the factor)  or other 
appropriate statistic s detailed in the SAP  to assess the difference between VIS410 
treatment groups  vs placebo in the area under the viral load- time curve (AUC) for 
influenza virus based on quantification of viral load from nasal swabs  
Visterra Inc.
VIS410-202 Clinical Study Report
CONFIDENTIAL
Page 49 of 75
• Descriptive statistics of the area under the viral load -time c urve (AUC) for influenza 
virus based on quantification  of viral load from nasopharyngeal swabs by [CONTACT_6490]. 
• Descriptive statistics of the time to resolution of viral load and of the peak viral load 
by [CONTACT_1570]. 
The mITT population will be used for the summaries.  
9.3.5 Signs and Symptoms of Influenza  
The difference between VIS410 and placebo will be assessed as outlined below. 
• Frequency  tabulation of the occurrence and severity of each of the subject -reported 
symptoms of influenza- like illness by [CONTACT_618025]  
• Descriptive statistics of the duration of each of the subject -reported symptoms of 
influenza- like illness by [CONTACT_618055]. The mITT  population will be 
used for the summaries. Additional populations may be analyzed as described in the SAP .  
9.3.6 Immunology  
Immunological assessments will be summarized by [CONTACT_46642], treatment group, and time point using descriptive statistics: 
• Anti-VIS410 antibody titers by [CONTACT_618032] 
• Anti-influenza A antibodies by [CONTACT_618033] 
• HAI levels to determine a proper immune response to the influenza infection 
The mITT population will be used for the summaries.  Additional populations may be 
analyzed as described in the SAP . 
Anti-Drug Antibodies 
Anti-VIS410 antibody titer will be summarized by [CONTACT_618056].  
9.3.7 Exploratory Pharmacokinetic/Pharmacodynamic An alyses  
Various techniques will be used to explore exposure-response relationships, and to compare the strength of the relationship between each independent variable (e.g., AUC, C
max, and 
concentration at specific time  point) and the dependent variables (e.g., viral AUC, peak viral 
load, and time to cessation of viral shedding, clinical symptoms , and additional endpoints). 
These techniques may include graphical and statistical methods, including the creation of boxplots, spaghetti plots, histograms, and a variety of linear, nonlinear, or logistic regression techniques and time- to-event methods. If appropriate, continuous independent variables will 
be evaluated as such, and as categorical variables (groupi[INVESTIGATOR_617980]).  
Visterra Inc.
VIS410-202 Clinical Study Report
CONFIDENTIAL
Page 50 of 75
9.3.8 Safety  
The ITT, and safety  populations will be used for the safety summaries.  Additional 
populations may be analyzed and this will be documented in the SAP . 
Adverse Events  
The original terms in the EDC  system by [CONTACT_10670] s to identify AEs other than symptoms 
of infl uenza A will be fully described and coded according to the Medical Dictionary for 
Regulatory Activities (MedDRA  current version 19 ). The reported AEs will be allocated to 
phases based on their start date. All AEs will be listed. All AEs with onset during the 
treatment phase (TEAEs) will be summarized.   
AEs will be summarized by [CONTACT_618057], severity, relatedness, and seriousness. Classical symptoms of influenza including cough, sore throat, nasal congestion, fatigue, headache, myalgia or low- grade fever 
should not be reported as AEs unless there is a relationship between the event and study medication.  
The difference in proportions of subjects with AEs, TEAEs, AESIs, and SAEs between treatment groups and their 95% CI will be calculated (primary safety endpoint). 
Special attention will be paid to those subjects  who died, discontinued the study drug due to 
an AE, or experienced a severe or serious AE. Summaries, listings, and narratives (also see Section  
12.11 ) may be provided, as appropriate. 
Injection Site Tolerability  
Injection site tolerability is defined as  AEs demonstrating significant injection site irritation 
or tissue damage. Injection site tolerability will be reported by [CONTACT_72246], treatment group, and time point.  
Complications of Influenza  
Complications of influenza are defined as pneumonia, myocarditis, worsening of chronic bronchitis, other chronic pulmonary diseases, otitis, sinusitis, and death. Complications of influenza will be reported by [CONTACT_72246], treatment group, and time point. 
Clinical Laboratory Tests 
Actual values and changes from baseline of each continuous biochemistry, hematology and urinalysis test will be evaluated using descriptive statistics by [CONTACT_618025]. For categorical urinalysis tests, frequency tables of actual values will be provided by [CONTACT_618025]. 
Relative changes in clinical laboratory test values compared with values at baseline will be evaluated  in according to the Division of Microbiology and Infectious Diseases ( DMID ) 
grading table or in accordance with the normal ranges of the clinical laboratory (below, within, or above normal range) for parameters for which no toxicity grades are defined. A 
shift from baseline table of abnormalities in clinical laboratory test parameters will be provided by [CONTACT_618025]. 
Visterra Inc.
VIS410-[ADDRESS_820885] result outside the reference ranges will 
be provided. 
Vital Signs  
Actual values and changes from baseline of heart rate,  respi[INVESTIGATOR_697],  temperature, SBP , and 
DBP measurements will be evaluated by [CONTACT_618058]. 
A shift from baseline table of vital sign abnormalities  will be provided by [CONTACT_618059]. 
Electrocardiography 
The ECG variables that will be analyzed are heart rate, PR interval, QRS interval, and QT interval. Values for QT corrected for heart rate (QTc) will be derived. QTc corrected 
according to Fridericia (QTcF)  [
6] will be the primary correction parameter.  
Actual values and changes from baseline of ECG variables will be evaluated by [CONTACT_618060]. 
A shift from baseline table of ECG abnormalities will be provided by [CONTACT_618025]. For absolute QTcF interval prolongation (>450, >480, >500 ms ec) 
and changes from baseline (increase >30 and >60 ms ec), a frequency table by [CONTACT_618061]. 
Physical Examination 
Abnormal findings in physical examination will be listed.  
9.4 INTERIM ANALYSIS  
The following optional safety and efficacy interim analys es may be performed at the 
following times: 
• After [ADDRESS_820886] completed the Day 28 visit  
• After all enrolled subjects have completed the Day [ADDRESS_820887] with the planning of future studies. The statistician performing the analysis and the PK/PD team at Visterra may be unblinded.  
 
Visterra Inc.
VIS410-[ADDRESS_820888], and then has worsening of 
an AESI (severity of symptoms), then this event should also be reported. 
b The entire study period is from the time a subject receives the study drug through the Day [ADDRESS_820889] be notified within 24 hours of the site’s knowledge of the 
pregnancy; the subject or partner will be followed until the end of the pregnancy; and the infant will be 
followed for [ADDRESS_820890] medical occurrence in a patient  administered a medicinal 
(investigational or non-investigational) product in a clinical study . An AE does not 
necessarily have a causal relationship with the treatment. An AE can therefore be any 
unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non- investigational) 
product, whether or not related to that medicinal (investigational or non- investigational) 
product. 
This includes any occurrence that is new in onset or aggravated in severity or frequency from the baseline condition, or abnormal results of diagnostic procedures, including clinical laboratory test abnormalities.  
New or worsening symptoms of influenza including cough, sore throat, nasal congestion, fatigue, headache, myalgia or low -grade fever should not be reported as AEs unless they 
result  in an SAE (i.e., lead to hospi[INVESTIGATOR_059]) . 
Adverse Event of Special Interest  
An AESI  (serious or non-serious) is one of scientific and medical concern specific to the 
Sponsor’s product or program, for which ongoing monitoring and rapid communication by [CONTACT_618062] . Such an event might warrant further 
investigation in order to characterize and understand it. Depending on the nature of the event, rapid communication by [CONTACT_13659] (e.g., regulators) might also be warranted (based on CIOMS VI). 
For VIS410, the AESIs include the following: 
• Abdominal crampi[INVESTIGATOR_007]  
• Diarrhea  
• Nausea and vomiting 
• Pruritus  
• Rash  
Visterra Inc.
VIS410-202 Clinical Study Report
CONFIDENTIAL
Page 53 of 75
• Hypotension 
• Throat tightening  
• Trouble breathing or wheezing 
 
Serious Adverse Event  
An SAE is any untoward medical occurrence that at any dose meets any of the following 
conditions: 
• results in death  
• is life -threatening, i.e., the patient  was at risk of death at the time of the event (e.g., 
ventricular fibrillation and anaphylaxis). The term does not re fer to an event which 
hypothetically might have caused death if it were more severe.  
• requires inpatient hospi[INVESTIGATOR_148244]: 
Hospi[INVESTIGATOR_618003]/or treating the AE. Hospi[INVESTIGATOR_34096], or 
routinely scheduled treatment for a pre-existing condition that has not worsened, is 
not an SAE. 
• results in persistent or significant disability/incapacity, i.e., causing substantial 
disruption of the patient ’s ability to conduct normal life 
• is a congenital anomaly/birth defect  
• is medically significant, i.e., may not be immediately life -threatening or result in 
death or hospi[INVESTIGATOR_618004]’s health or may require 
intervention to prevent one of the above outcomes. Examples of such events are intensive treatment in an emergency room or at home for allergic bronchospasm, blood dyscrasias, or convulsions that do not result in hospi[INVESTIGATOR_456004]. 
Unlisted (Unexpected) Adverse Event  
An AE is considered unlisted if the nature or severity is not consistent with the applicable 
product reference safety information (Investigator Brochure [ 5]). 
Suspected Unexpected Serious Adverse Reactions  
Suspected unexpected serious adverse reactions (S[LOCATION_003]Rs) are SAEs that are unexpected and judged by [CONTACT_618063].  
The Sponsor or designee will report S[LOCATION_003]Rs and other applicable SAEs to the appropriate regulatory authorities, Central I nstitutional Review Board (I RBs)/Ethics Committees ( ECs) 
and Investigators as required, according to local law. 
Treatment -Emergent Adverse Event  
A TEAE is defined as any event not present prior to the initiation of the treatments or any event already present that worsens in either intensity or frequency following exposure to the treatments.  
10.[ADDRESS_820891] be rated on a 3-point scale of increasing intensity according to DMID (
Appendix 2 ): 
Visterra Inc.
VIS410-202 Clinical Study Report
CONFIDENTIAL
Page 54 of 75
Note : the semi-colon within the description of the grade indicates ‘or’.  
Grade 1  Mild transient or mild discomfort (<48 hours); no medical intervention/therapy 
required  
Grade 2  Moderate/mild to moderate limitation in activity —some assistance may be 
needed; no or minimal medical intervention/therapy required 
Grade 3  Severe/marked limitation in activity, some assistance usually required; medical intervention/therapy required, hospi[INVESTIGATOR_29125]  
 
10.[ADDRESS_820892] treatment:  
Reasonable Possibility  
There is evidence to suggest a causal relationship between the test treatment and the AE (e.g., 
AE is uncommon and known to be strongly associated with drug exposure or is uncommon in the study population, but not commonly associated with drug exposure). 
No Reasonable Possibility 
There is no evidence to suggest a causal relationship between the test treatment and the AE.  
10.[ADDRESS_820893] be described as follows: 
• Permanently discontinued 
• Stopped temporarily 
• Modified infusion rate 
• No action Taken  
• Not applicable  
10.[ADDRESS_820894] be rated as follows: 
• Recovered/resolved  
• Recovering/resolving  
• Not recovered/not resolved 
• Recovered with sequelae/resolved with sequelae 
• Fatal  
• Unknown 
10.6 RECORDING OF ADVERSE EVENTS  
All (S)AEs occurring during the clinical investigation must be documented in the EDC  
system.  
Visterra Inc.
VIS410-202 Clinical Study Report
CONFIDENTIAL
Page 55 of 75
Whenever possible, diagnoses should be given when signs and symptoms are due to a 
common etiology (e.g., skin erythema, induration, edema and warmth should be reported as “cellulitis ”). Investigators must record their opi[INVESTIGATOR_140020] (S)AE 
to the study drug in the EDC  system. All measures required for (S)AE management must be 
recorded in the source documents and reported according to Sponsor’s instructions. 
All (S)AEs occurring at any time during the study (including the follow-up period) will be 
f
ollowed by [CONTACT_324763] (e.g., value back to baseline value) 
or stabilization or until final database lock. If necessary, in order to obtain additional information to ensure safety to the subject, additional blood and urine samples may be taken at the discretion of the I nvestigator. Certain long -term AEs related to therapy cannot be 
followed until resolution within the setting of this study. In these cases follow up will be the responsibility of the treating physician. 
10.[ADDRESS_820895] be reported on a Serious 
Adverse Event Form by [CONTACT_611145] 24 hours of their knowledge of the event, preferably by [CONTACT_6968]. Other means of transmission can be decided when email  is not possible ( fax).  
The Sponsor and Medical Monitor will be notified of SAEs within [ADDRESS_820896] details  for reporting SAEs :  
 
 
Contact [CONTACT_618064] -O lam Medical Monitor: 
 
 
 
The SAE form should include a clearly written narrative describing signs, symptoms, and t
reatment of the event, diagnostic procedures, as well as any relevant laboratory data and any 
sequelae, in order to allow a complete medical assessment  of the case and independent 
determination of the possible causality.  
Follow-up and outcomes should be reported for all subjects  that experience an SAE.  
It is critical that the information provided on the Serious Adverse Event Form matches the 
i
nformation recorded in the EDC  system for the same event. In addition, the same 
information is to be recorded in the source documents. 
Copi[INVESTIGATOR_618005]. 
Follow- up reports relative to the subject ’s subsequent course must be submitted to CRO  until 
the event has subsided or, in case of permanent impairment, until the condition stabilizes. 
10.[ADDRESS_820897] details:  
 
 
 
  
 
 
Pregnancy i s  not an SAE, however c ongenital abnormalities and birth defects in the offspring 
of male or female subjects should be reported as an SAE if the subject was pregnant during 
the study treatment period  or in the 60-day period after dosing of study drug. 
10.9 REPORTING OF SAE S TO COMPETENT AUTHORITIES /ETHICS 
COMMITTEES  
Visterra  or designee is  responsible for appropriate reporting of AEs to the regulatory 
authorities. Visterra or designee will also report to the Investigator all SAEs that are unlisted 
(unexpected) and associated with the use of the drug. The Investigator must report these events to the appropriate Independent Ethics Committee/Institutional Review Board (IEC/IRB) that approved the protocol, unless otherwise required and documented by [CONTACT_6179]/IRB.  
Visterra or designee, will be responsible for unblinding and submitting S[LOCATION_003]Rs involving t
he study drug to the applicable regulatory authoritie s according to International Conference 
on Harmonization ( ICH) guidelines. In addition, Visterra or designee, will be responsible for 
the submission of safety letters to the central IRB/EC and to participating Investigators of all 
S[LOCATION_003]Rs involving VIS410 according to applicable regulations. For clinical sites that use a local IRB/EC, it is the responsibility of the Investigator to promptly notify the local IRB/EC 
of all unexpected serious adverse drug reactions involving risk to human subjects.  
After termination of the clinical study ( d
 etermined as L SLV), any unexpected safety issue 
that changes the risk –benefit analysis and is likely to have an impact on the subjects  who 
have participated in it, will be reported by [CONTACT_618065](ies) concerned together with proposed actions. 
 
Visterra Inc.
VIS410-[ADDRESS_820898] their decision 
to continue participation. Subjects will be informed  that their consent to participate in the 
study is voluntary and m ay be withdrawn at any time with out the need to provide a reason 
and without penalty or loss of benefits to which they would otherwise be entitled. Only 
subjects  who are fully able to understand the risks, benefits, and potential AEs of the study, 
and provide their consent voluntarily will be enrolled. 
11.2 REGULATORY ETHICS COMPLIANCE  
11.2.1  Investigator Responsibilities  
The Investigator(s) should be qualified by [CONTACT_8640], training, and experience to assume 
responsibility for the proper conduct of the study, should meet all the qualifications specified 
by [CONTACT_8146](s), and should provide evidence of such qualifications through up- to-date curriculum vitae and/or other relevant documentation 
requested by [CONTACT_1034], the IRB/IEC, and/or the regulatory authority(ies). 
The Investigator is responsible for ensuring that the clinical study is performed in accordance 
with the protocol, current ICH guidelines on GCP, and applicable regulatory and country- specific requirements.  
Good Clinical Practice is an international ethical and scientific quality standard for designing, conducting, recording, and reporting studies that involve the participation of human subjects . 
Compliance with this standard provides public assurance that the rights, safety, and well-being of study subjects are protected, consistent with the principles that originated in the 
Declaration of Helsinki ; and that the clinical study data are credible.  
11.2.[ADDRESS_820899] 
An IRB/IEC should safeguard the rights, safety, and well- being of all study subjects. Special 
attention should be paid to studies that may include vulnerable subjects . 
Before the start of the stud y, the Investigator (or Sponsor where required) will provide the 
IEC/IRB with current and complete copi[INVESTIGATOR_23747]: 
• Final  protocol and, if applicable, amendments 
• Sponsor-approved ICF (and any updates ) and any other written materials to be  
provided to the subjects ; 
• Sponsor-approved subject recruiting materials  
• Investigator Brochure (or equivalent information) and addenda 
• available safety information  
• information on compensation for study-related injuries or payment to subjects for 
participat ion in the study, if applicable  
Visterra Inc.
VIS410-202 Clinical Study Report
CONFIDENTIAL
Page 58 of 75
• Investigator’s current curriculum vitae or other documentation evidencing 
qualifications (unless not required, as documented by [CONTACT_8134]/IRB) 
• information regarding funding, name [CONTACT_19618] , institutional affiliations, other 
potential conflicts of interest, and incentives for subjects ; 
• any other documents that the IEC/IRB may req uire to fulfill its obligation  
This study will be undertaken only after the IEC/IRB has given full written approval of the 
final protocol and amendments (if any), the ICF (s) and updates (if any ), applicable recruiting 
materials, and any other written information to be provided to the subjects , and the Sponsor 
has received a copy of this approval. This approval letter must be dated and must clearly identify the IEC/IRB and the documents being approved. 
During the study, the I nvestigator (or Sponsor where required) will send the following 
documents and updates to the IEC/IRB for their review and approval, where appropria te:  
• protocol amendments 
• revision(s) to ICF and any other written mater ials to be provided to subjects ; 
• if applicable, new or revised subject  recruiting materials  approved by [CONTACT_1034]; 
• revisions to compensation for study-related injuries or payment to s ubjects  for 
participat ion in the study, if applicable 
• Investigator’s Broc hure addenda or new edition(s) 
• summaries of the status of the study at intervals stipulated in guidelines of the 
IEC/IRB (at least annually)  
• reports of AEs that are serious, unlisted, and associated with the investigational drug 
• new information that may adversely affect the safety of the subjects  or the conduct of 
the study 
• deviations from or changes to the protocol to eliminate im mediate hazards to the 
subjects ; 
• report of deaths of subjects under the I nvestigator’s care  
• notification if a new Investigator is responsible for the study at the site  
• Development Safety Update Report, Short Term Study Specific Safety Summary and Line Listings, where applicable  
• any ot her requirements of the IEC/IRB  
For all protocol amendments (excluding the ones that are purely administrative, with no 
consequences for subjects , data or study conduct), the amendment and applicable ICF 
revisions must be submitted promptly to the IEC/IRB for review and approval before implementation of the change(s), except when necessary to eliminate immediate hazard to the study subjects . If a deviation from, or a change to the protocol was implemented to eliminate 
an immediate hazard to study subjects , then the implemented deviation or change, the reasons 
for it, and, if appropriate, the protocol amendment should be submitted to the IEC/IRB as soon as possible. 
The Investigator (or Sponsor where required) will notify the IEC/IRB about the study 
completion  within 90 days after the end of the study ( defined as L SLV). 
Visterra Inc.
VIS410-[ADDRESS_820900] be approved by [CONTACT_19597]/IRB. The informed consent should be in accordance with principles that originated in the Declaration of Helsinki, current ICH and GCP guidelines, applicable regulatory requirements, and Sponsor policy. 
Before enrollment in the study, the Investigator or an authorized member of the investigational staff must explain to potential subjects  the aims, methods, reasonably 
anticipated benefits, and potential hazards of the study, and any discomfort participation in the study may entail. Subjects  will be informed that their participation is voluntary and that 
they may refuse to participate or withdraw consent to participate at any time , without penalty 
or loss of benefits to which the subject  was entitled . Finally, they will be told that the 
Investigator will maintain a subject  identification re gister for the purposes of long- term 
follow up if needed and that their records may be accessed by [CONTACT_618066], to the extent permitted by [CONTACT_6983](s) or regulations. By [CONTACT_441263], and agrees to allow his or her study physician to re- contact [CONTACT_441264], if needed.  
The language used in the oral and written information about the study, including the ICF, should be non-technical and practical and should be understandable to the subject  or the 
subject’s legal representative. The subject  will be given sufficient time to read the ICF and 
the opportunity to ask questions. After this explanation and before entry into the study, consent should be appropriately recorded by [CONTACT_19720]'s personally dated signature. After having obtained the consent, a copy of the ICF must be given to the subject . 
If the subject  is unable to read or write, an impartial witness should be present for the entire 
informed consent process (which includes reading and explaining all written information) and should personally date and sign the ICF after the oral consent of the subject  is obtained, if 
permitted by [CONTACT_1769].  
11.2.4  Privacy of Personal Data  
The collection and processing of personal data from subjects  enrolled in this study will be 
limited to those data that are necessary to investigate the safety, quality, and utility of the investigational study drug(s) used in this study. 
These data must be collected and processed with adequate precautions to ensure confidentiality and compliance with applicable data priva cy protection laws and regulations. 
Appropriate technical and organizational measures to protect the personal data against unauthorized disclosures or access, accidental or unlawful destruction, or accidental loss or alteration must be put in place. Sponsor personnel whose responsibilities require access to personal data agree to keep the identity of study subjects  confidential. 
The informed consent obtained from the subject  includes explicit consent for the processing 
of personal data and for the I nvestigator to allow direct access to his or her original medical 
Visterra Inc.
VIS410-202 Clinical Study Report
CONFIDENTIAL
Page 60 of 75
records for study -related monitoring, audit, IEC/IRB review, and regulatory inspection. This 
consent also addresses the transfer of the data to other entities and to other countries. 
 
12. ADMINI STRATIVE REQUIREMENT S 
12.[ADDRESS_820901] not be implemented without prior IEC/IRB 
approval, or when the relevant competent authority has raised any grounds for non-acceptance, except when necessary to eliminate immediate hazards to the subjects , in 
which case an amendment must be promptly subm itted to the IEC/IRB and relevant 
competent authority. Documentation of amendment approval by [CONTACT_67830]/IRB must be provided to the Sponsor or its designee. When the change(s) involves only logistic or administrative aspects of the study, th e IRB (and IEC where required) only needs 
to be notified. 
12.[ADDRESS_820902]  confidentiality , no copy will be made. 
All reports and communications relating to the study will identify subjects  by [CONTACT_396949]/or 
assigned number only. 
The Investigator must also complete a subject -screening log, which reports on all subjects  
who were seen to determine eligibility for inclusion in the study. 
12.[ADDRESS_820903] be available for the following: subject  
identification, eligibility, and study identification; date of informed c onsent, dates of visits, 
results of safety and efficacy parameters as required by [CONTACT_760], record of all AEs, follow up of AEs, concomitant medication, drug receipt/dispensing/return records, study drug 
Visterra Inc.
VIS410-202 Clinical Study Report
CONFIDENTIAL
Page 61 of 75
administration information, laboratory printouts (if not available digitally ), date of study 
completion, and reason for early discontinuation of study drug or withdrawal from the study, 
if applicable.  
It is recommended that the author of an entry in the (e -)source documents be identifiable. 
Source data may be directly captured from devices, transf erred from third parties 
(e.g.,  laboratory data), or entered manually into the EDC  system in use at the clinical center. 
In such case, the majority of the source data will only be available electronically. The remainder of the data, captured initially on paper, may be entered retrospectively into the EDC  system.  
Following the ICH/ GCP guidelines, direct access to (e -)source documentation (medical 
records) must be allowed.  
12.[ADDRESS_820904] (s). If electronic records are maintained 
at the investigational site, the method of verification must be discussed with the investigational staff.  
Direct access to (e- )source documentation (medical records) must be allowed at all times for 
the purpose of verifying that the data recorded EDC  system are consistent with the original 
(e-)source data. Findings from this review of captured data will be discussed with the 
investigational staff. During on-site monitoring visits (notified and agreed upfront with the investigational staff), the relevant investigational staff will be available, the (e-)source 
documentation will be accessible, and a suitable environment will be provided for review of study-related documents. The M onitor will meet with the Investigator on a regular basis 
during the study to provide feedback on the study conduct. 
12.6 DATA MANAGEMENT  
Data management of the study will be p erformed under the responsibility of the Sponsor by  
[CONTACT_2024] . 
Visterra Inc.
VIS410-202 Clinical Study Report
CONFIDENTIAL
Page 62 of 75
After the data are released by [CONTACT_618067], the data will be uploaded into the clinical database to perform 
cleaning activ ities. Only the data of randomized subjects  will be captured in the clinical 
database.  
Computerized data cleaning checks will be used in addition to manual review including listings review, to check for discrepancies and to ensure consistency and completeness of the data. Queries emerging during data cleaning will be generated by [CONTACT_618068]. The Investigator or his designee will answer the queries and update the 
source data, if needed.  Any changes required are to be document ed with a full audit trail 
within the EDC  system.  
An interim lock of the database will occur at the time of the interim analysis (see Section  
9.4).  
The final clinical database will be locked as soon as it is considered clean. Only authorized and well -documented updates to the study data are possible after final database lock. The 
locked final database is used in the final statistical analysis for study reporting. Measures will be undertaken to protect subject  data handed over by [CONTACT_618069]. Subject  confidentiality will be maintained at all times.  
12.7 DATA QUALITY ASSURANCE  
The accuracy and reliability of the study data will be  assured by [CONTACT_495008], review of protocol procedures with the Investigator and associated personnel prior to the study, and by [CONTACT_618070]. 
Written instructions will be  provided for the collection, preparation, and shipment of samples.  
The Sponsor or its  designee will review the EDC  system for accuracy and completeness 
during (on- site) monitoring visits and after transmission to the Sponsor ; any discrepancies 
will be resolved with the Investigator or designee, as appropriate. After upload of the data 
into the clinical study database, they will be verified for accuracy.  
In accordance with Good Clinical Research Practice Guidelines and Recommendations, the Sponsor will be entitled to audit the facilities used in the clinical and laboratory parts of the study , as well as to access  all the data files pertaining to the study. Similar procedures may 
also be conducted by [CONTACT_67840], either as part of a national GCP compliance program or to review the results of this study in support of a regulat ory 
submission. The Investigator should immediately notify the Sponsor if they have been contact[CONTACT_426] a regulatory agency concerning an upcoming inspection. 
12.[ADDRESS_820905] been contact[CONTACT_426] a regulatory agency  concerning an upcoming inspection. 
12.9 STUDY TERMINATION  
The Sponsor reserves the right to terminate the study at any time. In case of an early termination of the study for safety reasons, or temporary halt by [CONTACT_1034], the IEC/IRB 
should be notified within 15 calendar days, including a detailed written explanation of the reasons for the termination/halt.  
The end -of-study declaration will be submitted to the regulatory authorities and IEC after the 
complete study has ended. This notification will also be submitted within [ADDRESS_820906] RETENTION  
In compliance with the ICH/GCP guidelines, the I nvestigator/institution will maintain an 
archived copy of the EDC  data and all paper source documents that support the data collected 
from ea ch subject , as well as all study documents as specified in ICH/GCP Section 8, 
Essential Documents for the Conduct of a Clinical Trial, and all study documents as specified by [CONTACT_8146](s). The I nvestigator/institution will take measures to 
prevent accidental or premature destruction of these documents. 
Essential documents must be retained until at least [ADDRESS_820907]. These documents will be retained for a longer period if required by [CONTACT_67836] . It is the responsibility of the Sponsor to inform the 
Investigator/institution as to when these documents no longer need to be retained.  
If the responsible Investigator retires, relocates, or for other reasons withdraws from the responsibility of keepi[INVESTIGATOR_8090], custody must be transferred to a person who will accept the responsibility. The Sponsor must be notified in writing of the name [CONTACT_1640]. Under no circumstance shall the Investigator relocate or dispose of any 
study documents before having obtained written approval from the Sponsor. 
If it becomes necessary for the Sponsor or the appropriate regulatory authority to revi ew any 
documentation relating to this study, the Investigator must permit access to such reports. 
12.11  USE OF INFORMATION AND PUBLICATION  
All information, including but not limited to information regarding VIS410 or the Sponsor’s operations (e.g., patent application, formulas, manufacturing processes, basic scientific data, 
Visterra Inc.
VIS410-202 Clinical Study Report
CONFIDENTIAL
Page 64 of 75
prior clinical data, formulation information) supplied by [CONTACT_618071], and any data generated as a result of this study are considered confidential and remain the sole property of the Sponsor. The I nvestigator agrees to maintain 
this information in confidence, to use this information only to accomplish this study, and not to use it for other purposes without the Sponsor’s prior written consent. 
The Investigator understands that the information developed in this  clinical study will be used 
by [CONTACT_618072], and thus may be disclosed as required to other clinical Investigator s or regulato ry agencies. To permit 
the information derived from the clinical studies to be used, the I nvestigator is obligated to 
provide the Sponsor with all data obtained in the study.  
The results of the study will be reported in a Clinical Study Report written  by [CONTACT_618073]. Recruitment performance or specific expertise related to the nature and the key assessment parameters of the study wi ll be us ed to determine a 
coordinating I nvestigator. 
Clinical narratives will be written for th e following events: 
• All deaths (irrespective of drug relationship)  
• All other SAEs during treatment with the study drug  
• All discontinuation s of the study due to AEs related to the study drug 
• At the discretion of the team and after statistical analysis of the data, certain 
discontinuations not related to AEs or treatment failure, i.e., related to lost to 
follow up or withdrawal of consent (i rrespective of treatment group) 
• Any events of special interest explicitly requested by [CONTACT_397149]  
A summary of this final version will be provided to the Investigators, to the applicable 
regulatory authorities, and IECs/IRBs, if required by [CONTACT_1214], within 1 year of the end of the study (Last Subject Last Visit).  
The Sponsor shall have the right to publish such data and information without approval from the Investigator. 
Individual site publications are not expected as individual sites m ay not recruit enough 
subjects  to enable detailed publications; therefore, results of this study will be reported in 
total.  
If an Investigator wishes to publish information from the study, a copy of the manuscript 
must be provided to the Sponsor for review  at least [ADDRESS_820908] made a significant contribution to the 
Visterra Inc.
VIS410-202 Clinical Study Report
CONFIDENTIAL
Page 65 of 75
design of the study or analysis and interpretation of the data, provided critical review of the 
paper, and given final approval of the final version. 
12.12  REGISTRATION OF CLINICAL STUDIES AND DISCLOSURE OF RESULTS  
The Sponsor will register and/or disclose the existence of and the results of clinical studies as required by [CONTACT_2371]. 
12.13  CONFIDENTIALITY  
All study documents are provided by [CONTACT_96977]/her appointed staff. None of this material may be disclosed to any party not directly involved in the study without Sponsor ’s written permission.  
The Investigator must assure that subject ’s anonymity will be maintained. The Investigator  
will keep a separate list with at least the initials, the subject ’s study numbers, names, 
addresses, and telephone numbers. The I nvestigator  will maintain this for the longest period 
of time allowed by [CONTACT_5657]/her own institution and, in any case, until further communication from the Sponsor. 
 
13. REFERENCES 
1. Treanor JJ, Hayden FG, Vrooman PS, et al, Efficacy and safety of the oral 
neuraminidase inhibi tor oseltamivir in treating acute influenza: a randomized 
controlled trial. US Oral Neuraminidase Study Group. JAMA. 2000;283(8):1016–024. 
2. Schanzer DL, Langley JM, Tam TW. Co -morbidities associated with 
influenza-attributed mortality, 1994-2000, Canada. Vaccine. 2008;26(36):4697–703. 
3. CDC. Estimates of deaths associated with seasonal influenza US, 1976-2007. MMWR. 2012;59(33):1057–62. 
4. Babcock G, Szretter K, Sloan S, et al. VIS410, a broadly HA -targeting human 
antibody, neutralizes H5 and H7 isol ates with p andemic potential. ICAAC, Denver, 
2013. 
5. Investigator Brochure of VIS410, version 4.0, 2015. 
6. Fridericia LS. The duration of systole in the electrocardiogram of normal subjects and of subjects  with heart disease. Acta Medica Scandinavica. 1920;53:469–86. 
7. Watson JM, Francis JN, Mesens S, et al. Characterisation of a wild-type influenza (A/H1N1) virus strain as an experimental challenge agent in humans. Virol J. 2015;12(1):13. 
Visterra Inc.
VIS410-202 Clinical Study Report
CONFIDENTIAL
Page 66 of 75
APPENDIX 1: LABORATORY ASSESSM ENTS  
Urinalysis  Hematology  Chemistry  
Dipstick:  Hemoglobin  Albumin  
• Specific gravity  Hematocrit  Alkaline phosphate  
• pH Red blood cells (RBC)  Alanine amino transferase  
• Glucose  White blood cells (WBC) with 
differential  Aspartate amino transferase  
• Protein  Lymphocytes  Bicarbonate  
• Blood  Monocytes  Total bilirubin  
• Ketones  Neutrophils c Direct bilirubin b 
• Bilirubin  Eosinophils  Blood urea nitrogen (or urea)  
• Urobilinogen  Basophils  Calcium  
• Nitrite  Platelets  Chloride  
• Leukocyte esterase   Creatinine  
   Glucose a  
Urine sedimentation count:   Lactate dehydrogenase  
• Erythrocytes (RBC)   Phosphate, inorganic  
• Leukocytes (WBC)   Potassium  
• Epi[INVESTIGATOR_618006] -MB d, 
creatinine kinase d, troponin d • Crystals   
• Casts    
• Bacteria    
Serology  a  Other Assessments  Coagulation  
Antibody screening test  
(immunoassay), rapid  HIV test  Urine pregnancy test  Partial thromboplastin time  
 Activated partial thromboplastin 
time 
a Screening only  
b Assay if total bilirubin is above normal range.  
c If immature neutrophils are detected, the sample is to be flagged and a blood slide for microscopic analysis 
will be made. If Bands are detected in the microscopic analysis, then a result will be provided.   
d Only measure if subject has chest pain.  
 
Visterra Inc.
VIS410-202 Clinical Study Report
CONFIDENTIAL
Page 67 of 75
APPENDIX 2: DMID ADULT TOXICITY TABLE  
 
ABBREVIATIONS : Abbreviations utilized in the Table:  
ULN = Upper Limit of Normal LLN = Lower Limit of Normal  
Rx = Therapy  Req = Required  
Mod = Moderate IV = Intravenous 
ADL = Activities of Daily Living  Dec = Decreased  
 
ESTIMATING SEVERITY GRADE  
For abnormalities  NOT found elsewhere in the Toxicity Tables use the scale below to 
estimate grade of severity:  
GRADE 1  Mild Transient or mild discomfort (< 48 hours); no medical 
intervention/therapy required 
GRADE 2  Moderate Mild to moderate limitation in activity - some assistance may be needed; no or minimal medical intervention/therapy required 
GRADE 3  Severe Marked limitation in activity, some assistance usually required; medical intervention/therapy required, hospi[INVESTIGATOR_281925] 4  Life-threatening Extreme limitation in activity, significant assistance 
required; significant medical intervention/therapy required, hospi[INVESTIGATOR_618007] -THREATENING AEs  
ANY clinical event deemed by [CONTACT_135956]-threatening should be 
considered a grade 4 event. Clinical events considered to be serious or life- threatening 
include, but are not limited to: seizures, coma, tetany, diabetic ketoacidosis, disseminated intravascular coagulation, diffuse petechiae, paralysis, acute psychosis, severe depression.  
COMMENTS REGARDING THE USE OF THESE TABLES  
• Standardized and commonly used toxicity tables (Division of AIDS, NCI’s Common 
Toxicity Criteria (CTC), and World Health Organization (WHO)) have been adapted 
for use by [CONTACT_618074].  
• For parameters not included in the following Toxicity Tables, sites should refer to the 
“Guide For Estimating Severity Grade” located above.  
• Criteria are generally grouped by [CONTACT_6764].  
• Some protocols may have additional protocol specific grading criteria, which will supercede the use of these tables for specified criteria. 
 
Visterra Inc.
VIS410-202 Clinical Study Report
CONFIDENTIAL
Page 68 of 75
HEMATOLOGY  
 Grade 1  Grade 2  Grade 3  Grade 4  
Hemoglobin  9.5 - 10.5 g/dL 8.0 - 9.4gm/dL  6.5 - 7.9 g/dL < 6.5 g/dL 
Absolute Neutrophil Count  1000 -1500/ mm3  750-999/ mm3  500-749/ mm3 <500/ mm3 
Platelets  75,000 - 
99,999/ mm3 50,000 - 
74,999/ mm3 20,000 -49,999/ mm3 <20,000/ mm3 
WBCs  11,000 -13,000/mm3 13,000 -15,000/mm3 15,000 -30,000/ mm3 >30,000 or  
<1,000/mm3 
% Polymorphonuclear  
Leucocytes + Band Cells  > 80%  90 – 95% >95%  ----------  
Abnormal Fibrinogen  Low:  
100-200 mg/dL  
 
High:  
400-600 mg/dL  Low:  
<100 mg/dL  
 
High:  
>600 mg/dL  Low:  
< 50 mg/dL  
 
---------- Fibrinogen  
associated with 
gross bleeding or 
with disseminated 
coagulation  
Fibrin Split Product  20-40 mcg/ m L 41-50 mcg/ mL 51-60 mcg/ mL > 60 mcg/ mL 
Prothrombin Time (PT)  1.[ADDRESS_820909]  >[ADDRESS_820910]  
Activated Partia l 
Thromboplastin (APPT)  1.[ADDRESS_820911]  > [ADDRESS_820912]  
Methemoglobin  5.0 - 9.9 %  10.0 - 14.9 %  15.0 - 19.9%  > 20.0 %  
 
Visterra Inc.
VIS410-202 Clinical Study Report
CONFIDENTIAL
Page 69 of 75
CHEMISTRIES  
 Grade 1  Grade 2  Grade 3  Grade 4  
Hyponatremia  130-135 mEq/ L  123-129 mEq/ L  116-122 mEq/ L  < 116 mEq/ L or  
abnormal sodium  with 
mental  
status changes or  seizures  
Hypernatremia  146-150 mEq/ L  151-157 mEq/ L  158-165 mEq/ L  > 165 mEq/ L or  
abnormal sodium  with 
mental  
status changes or  seizures  
Hypokalemia  3.0 - 3.4 mEq/ L  2.5 - 2.9 mEq/ L  2.0 - 2.4 mEq/ L  or 
intensive  
replacement  therapy 
or hospi[INVESTIGATOR_618008]  < 2.0 mEq/ L or  
abnormal  potassium with 
paresis, ileus or  life-
threatening  arrhythmia  
Hyperkalemia  5.6 - 6.0 mEq/ L  6.1 - 6.5 mEq/ L  6.6 - 7.0 mEq/ L > 7.0 mEq/ L  or 
abnormal  
potassium with life-
threatening  arrhythmia  
Hypoglycemia  55-64 mg/dL  40-54 mg/dL  30-39 mg/dL  <30 mg/ dL or abnormal 
glucose  with mental  
status changes or  coma  
Hyperglycemia  
(nonfasting and no prior  
diabetes)  116 - 160 mg/dL  161- 250 mg/dL  251 - 500 mg/dL  > 500 mg/ dL or abnormal 
glucose  with ketoacidosis  
or seizures  
Hypocalcemia  (corrected 
for albumin)  8.4 - 7.8 mg/dL  7.7 - 7.0 mg/dL  6.9 - 6.1 mg/dL  < 6.1 mg/dL  or abnormal  
calcium with life 
threatening  arrhythmia or  
tetany  
 
Visterra Inc.
VIS410-202 Clinical Study Report
CONFIDENTIAL
Page 70 of 75
CHEMISTRIES (continued)  
 Grade 1  Grade 2  Grade 3  Grade 4  
Hypercalcemia  (correct for 
albumin)  10.6 - 11.5 mg/dL  11.6-12.5 mg/dL  12.6 - 13.5 mg/dL  > 13.5 mg/dL or  
abnormal calcium  
with life threatening 
arrhythmia  
Hypomagnesemia  1.4 - 1.2 mEq/ L  1.1 - 0.9 mEq/ L  0.8 - 0.6 mEq/ L  < 0.6 mEq/ L or  
abnormal  magnesium 
with life-threatening 
arrhythmia  
Hypophosphatemia  2.0 - 2.4 mg/dL  1.5 -1.9 mg/dL  or 
replacement Rx  
required  1.0 -1.4 mg/dL  
intensive therapy  or 
hospi[INVESTIGATOR_618008]  < 1.0 mg/dL or  
abnormal  phosphate 
with life-threatening 
arrhythmia  
Hyperbilirubinemia (when  
accompanied by [CONTACT_618075])  1.1 - <1.[ADDRESS_820913]  1.25 - <1.[ADDRESS_820914]  1.5 – 1.[ADDRESS_820915]  > 1.[ADDRESS_820916]  
Hyperbilirubinemia (when  
other liver function are in 
the normal range)  1.1 - <1.[ADDRESS_820917]  1.5 - <2.[ADDRESS_820918]  2.0 – 3.[ADDRESS_820919]  > 3.[ADDRESS_820920]  > [ADDRESS_820921]  
Hyperuricemia (uric acid)  7.5 – 10.0 mg/dL  10.1 – 12.0 mg/dL  12.1 – 15.0 mg/ dL >15.0 mg/ dL 
Creatinine  1.[ADDRESS_820922]  > [ADDRESS_820923] (SGOT)  1.1 - <2.[ADDRESS_820924]  2.0 – <3.[ADDRESS_820925]  3.0 – 8.[ADDRESS_820926]  > [ADDRESS_820927]  
ALT (SGPT)  1.1 - <2.[ADDRESS_820928]  2.0 – <3.[ADDRESS_820929]  3.0 – 8.[ADDRESS_820930]  > [ADDRESS_820931]  
GGT  1.1 - <2.[ADDRESS_820932]  2.0 – <3.[ADDRESS_820933]  3.0 – 8.[ADDRESS_820934]  > [ADDRESS_820935]  
Alkaline Phosphatase  1.1 - <2.[ADDRESS_820936]  2.0 – <3.[ADDRESS_820937]  3.0 – 8.[ADDRESS_820938]  > [ADDRESS_820939]  > 5.[ADDRESS_820940]  > 5.[ADDRESS_820941]  
 
Visterra Inc.
VIS410-202 Clinical Study Report
CONFIDENTIAL
Page 71 of 75
URINALYSIS  
 Grade 1  Grade 2  Grade 3  Grade 4  
Proteinuria  1+ or 200 mg - 1 g 
loss/day  2-3+ or 1- 2 g 
loss/day  4+ or 2-3.5 g loss/day  nephrotic  syndrome  or 
>3.5 g loss/day  
Hematuria  microscopic only  <10 
RBC/ HPF gross, no clots  >10 
RBC/HPF  gross, with or  without 
clots, OR  red blood 
cell casts  obstructive or  
required  transfusion  
 
CARDIOVASCULAR  
 Grade 1  Grade 2  Grade 3  Grade 4  
Cardia c Rhythm   asymptomatic, 
transient signs, no  Rx 
required  recurrent/persistent; 
symptomatic Rx 
required  unstable dysrythmia;  
hospi[INVESTIGATOR_618009]  >20 
mm/ Hg; no treatment  recurrent, chronic 
increase  > 20mm/ Hg.  
/treatment required  acute treatment 
required; outpatient 
treatment or 
hospi[INVESTIGATOR_618010] 
<20 beat/min or 
decreased by <10 mm 
Hg systolic BP, No 
treatment required  symptoms due  to 
orthostatic 
hypotension or BP 
decreased by <20  mm 
Hg systolic; 
correctable with oral 
flu id treatment  requires IV fluids; no 
hospi[INVESTIGATOR_618011]  
<60mm/ Hg or end 
organ damage or 
shock; requires 
hospi[INVESTIGATOR_618012] r treatment  
Perica rditis minimal effusion  mild/ moderate 
asymptomatic 
effusion, no treatment  symptomatic 
effusion; pain; EKG 
changes  tamponade; 
pericardiocentesis or 
surgery required  
Hemorrhage, Bloo d 
Loss microscopic/occult  mild, no transfusion  gross blood loss;  1-2 
units transfused  massive blood loss; > 
3 units transfused  
 
RESPI[INVESTIGATOR_7382] 1  Grade 2  Grade 3  Grade 4  
Cough  transient - no 
treatment  persistent  cough;  
treatment  responsive  Paroxysmal cough;  
uncontrolled with  
treatment  --------------------  
Bronchospasm, Acute  transient; no  
treatment; 70% - 
80% FEV 1 of peak 
flow Requires treatment;  
normalizes with  
bronchodilator;  FEV 1 
50%-70% (of peak 
flow)  no normalization  
with bronchodilator;  
FEV 1 25% - 50% of 
peak flow; or  
retractions  present  cyanosis: FEV 1 
< 25% of peak 
flow or  intubation  
necessary  
Dyspnea  dyspnea on  exertion  dyspnea with  normal 
activity  dyspnea at rest  dyspnea requiring  
Oxygen therapy 
 
Visterra Inc.
VIS410-202 Clinical Study Report
CONFIDENTIAL
Page 72 of 75
GASTROINTESTINAL  
 Grade 1  Grade 2  Grade 3  Grade 4  
Nausea  mild or transient;  
maintains  reasonable 
intake  moderate  discomfort;  
intake  decreased  
significantly;  some 
activity  limited  no significant  
intake; requires IV  
flu ids  hospi[INVESTIGATOR_618008];  
Vomiting  1 epi[INVESTIGATOR_85712] 24  
hours  2-5 epi[INVESTIGATOR_11630]  
24 hours  >6 epi[INVESTIGATOR_11630] 
24 hours or needing  
IV fluids  physiologic  
consequences  
requiring 
hospi[INVESTIGATOR_618013];  
3-4 loose  stools/day 
or mild  diarrhea last 
<1 week  moderate or  persistent; 
5-7 loose stools/day  or 
diarrhea lasting >1 
week  >7 loose stools/day  
or bloody diarrhea;  
or orthostatic  
hypotension or  
electrolyte  
imbalance or >2  L 
IV fluids required  hypotensive  shock 
or physiologic  
consequences  
requiring 
hospi[INVESTIGATOR_618014]/Dysphagia  mild discomfort;  no 
difficulty  
swallowing  some limits on  
eating/drinking  eating/talking very  
limited; unable to  
swallow solid  foods  unable to drink  
fluids; requires  IV 
fluids  
 
Visterra Inc.
VIS410-202 Clinical Study Report
CONFIDENTIAL
Page 73 of 75
NEUROLOGICAL  
 Grade 1  Grade 2  Grade 3  Grade 4  
Neuro -Cerebellar  slight  incoordination  
dysdiadochokinesis  intention  tremor,  
dysmetria,  slurred 
speech;  nystagmus  locomotor ataxia  incapacitated  
Psychiatric  mild anxiety or  depression  moderate  anxiety 
or depression;  
therapy  required;  
change in  normal 
routine  severe mood  
changes requiring  
therapy; or suicidal 
ideation; or 
aggressive ideation  acute psychosis  
requiring 
hospi[INVESTIGATOR_059]; or 
suicidal 
gesture/attempt or 
hallucinations  
Muscle Strength  subjective  weakness  no 
objective  symptoms/ signs  mild objective  
signs/symptoms  no 
decrease in  
function  objective weakness  
function limited  paralysis  
Paresthesia (burning, 
tingling,  etc.) mild discomfort;  no 
treatment  required  moderate  
discomfort; non-
narcotic  analgesia 
required  severe discomfort;  or 
narcotic  analgesia 
required  with 
symptomatic  
improvement  incapacitating; or  
not responsive to  
narcotic analgesia  
Neuro -sensory  mild impairment in  
sensation  (decreased  
sensation, e.g.,  vibratory, 
pi[INVESTIGATOR_29107],  hot/cold in great 
toes) in focal area or 
symmetrical  distribution; 
or change in taste, smell, 
vision  and/or hearing  Moderate  
impairment  (mod 
decreased  
sensation, e.g.,  
vibratory,  pi[INVESTIGATOR_29107],  
hot/cold to  ankles) 
and/or  joint 
position or  mild 
impairment that  is 
not symmetrical  severe impairment  
(decreased or loss  of 
sensation to  knees or 
wrists) or  loss of 
sensation of  at least 
mod degree  in 
multiple  different 
body  areas (i.e., 
upper  and lower  
extremities)  sensory loss  
involves limbs  and 
trunk;  paralysis; or  
seizures  
 
MUSCULOSKELATEL  
 Grade 1  Grade 2  Grade 3  Grade 4  
Arthralgia  (joint pain)  mild pain not  
interfering with  
function  moderate pain,  
analgesics  and/or pain  
interfering with  function 
but not  with activities  of 
daily living  severe pain; pain  
and/or analgesics  
interfering with  
activities of daily  
living  disabling pain  
Arthritis  mild pain with  
inflammation,  
erythema or joint  
swelling – but not  
interfering with  
function  moderate pain  with 
inflammation,  erythema 
or joint swelling – 
interfering with  function, 
but not with  activities of  
daily living  severe pain with  
inflammation,  
erythema or joint  
swelling –and 
interfering with  
activities of daily  
living  permanent and/or  
disabling joint 
destruction  
Myalgia  myalgia with no 
limitation of  activity  Muscle  tenderness (at  
other than injection site)  
or with  moderate 
impairment of  activity  severe muscle  
tenderness with  
marked impairment  
of activity  Frank myonecrosis  
 
Visterra Inc.
VIS410-202 Clinical Study Report
CONFIDENTIAL
Page 74 of 75
SKIN  
 Grade 1  Grade 2  Grade 3  Grade 4  
Mucocutaneous  erythema; pruritus  diffuse, 
maculopapular 
rash,  dry 
desquamation vesiculation or  mist 
desquamation or  
ulceration  Exfoliative  dermatitis,  
mucous  membrane  
involvement or  erythema,  
mutiforme or  suspected  
Stevens -Johnson  or 
necrosis  requiring surgery  
Induration  < 15mm  15-30 mm  >30mm   
Erythema  < 15mm  15-30 mm  >30mm   
Edema  < 15mm  15-30 mm  >30mm   
Rash at Injection Site  < 15mm  15-30 mm  >30mm   
Pruritus  slight itching at  
injection site  moderate  itching 
at injection  
extremity  itching over entire  
body   
 
SYSTEMIC  
 Grade 1  Grade 2  Grade 3  Grade 4  
Allergi c Reaction  pruritus without  
rash localized  urticaria  generalized  
urticaria; 
angioedema  anaphylaxis  
Headache  mild, no treatment  
required  transient,  
moderate;  
treatment  required  severe; responds 
to initial narcotic  
therapy  intractable;  requires 
repeated  narcotic therapy  
Fever: oral  37.7 - 38.5 C or  
100.0 - 101.5 F  38.6 - 39.5 C or  
101.6 - 102.9 F  39.6 - 40.5 C or   
103 - 105 F  > 40 C or  
> 105 F  
Fatigue  normal activity  
reduced < 48 hours  normal activity  
decreased 25 -  
50% > 48 hours  normal activity  
decreased > 50%  
can’t work  unable to care for  self 
 
Visterra Inc.
VIS410-202 Clinical Study Report
CONFIDENTIAL
Page 75 of 75